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Removal of anti-A/B antibodies from blood in the peri-transplantation period eliminates the risk 
of hyperacute rejection in ABO-incompatible transplantation. We are developing anti-A/B 
immunoadsorption devices, compatible with whole blood perfusion. In this study we developed a 
new antibody filtering device based on integrated microfiltration fibers with antibody capturing 
beads distributed within the interstitial fiber space (BSAF device). As blood flows through the 
fibers in BSAF devices, Starling flow carries plasma from the inner fiber lumen to the beads in 
the shell compartment where antibodies diffuse and bind to covalently attached antigens within 
the shell-side porous beads. We first investigated the possibility of using synthetic blood group 
A/B-trisaccharide epitopes, conjugated with poly-N hydroxyethylacrylamide spacers, as the 
immunoadsorbent material in our antibody filtering devices. The glycopolymers were equipped 
with biotin tags and deposited on streptavidin-coated sensor chips. Antibody removal capacity 
per unit surface area and kinetics of antibody binding to immobilized glycoconjugates were 
quantified using surface plasmon resonance. We then developed a simple mathematical model to 
guide the choice of key design and operational parameters for a clinical BSAF device. The model 
demonstrated that for a given flow rate and reservoir volume, antibody removal rate in a BSAF 
was dependent on the magnitude of a lumped dimensionless parameter, sBL Qmk / , which  
characterized the ratio of antibody uptake rate by the beads to the Starling flow rate in the device. 
The highest antibody removal rate was predicted for a perfusion limited regime, when 
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10/ →sBL Qmk . Once this maximum limit was obtained, any further increase in the antibody 
removal rate was only possible by increasing the flow rate in the device.  Key model predictions 
were validated in a series of in vitro monoclonal anti-A antibody capture studies in BSAF 
devices packed with anti-A specific beads. Once validated, we used the model to design a BSAF 
device that would generate a clinically relevant rate of anti-A removal. We fabricated and tested 
scaled down prototypes of the “clinical” BSAF device and showed significant reduction in IgM 
and IgG anti-A antibody titers within two hours of whole blood perfusion through our fabricated 
BSAF devices.    
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1.0  INTRODUCTION 
The number of patients awaiting organ transplantation far exceeds the number of available 
cadaveric donor organs [1]. The average waiting time to obtain an ABO-compatible deceased 
donor kidney is approximately 3 years (UNOS/OPTN). Living donor organ transplantation 
provides a solution to the shortage of cadaveric donor organs, but an estimated 30-40% of living 
organ donor-recipient pairs are turned down due to ABO-incompatibility [2]. The main barrier to 
ABO-incompatible transplantation is the risk of hyperacute and acute allograft rejection [3]. 
Both types of rejection are triggered by binding of the host pre-existing anti-A/B antibodies to 
A/B antigens on the graft endothelium [3-5]. Antibody-antigen binding interactions activate the 
complement pathway and result in endothelial cell disruption, platelet adhesion and intravascular 
thrombosis. Hyperacute organ rejection follows as a result of  insufficient blood circulation in 
the graft [6]. However, immediate peri-transplantation removal of host anti-A/B antibodies 
eliminates the risk of hyper acute rejection and reduces the possibility of acute antibody 
mediated rejection to less than 30% [7]. Following initial successful ABO-mismatch renal 
transplantations reported by Alexandre et al. in 1985 [8], and Bannett et al. in 1987 [9] and the 
subsequent successful long term outcomes [10],[11],[12]. several  protocols have been developed 
and used in ABO-mismatch kidney, liver and heart transplantation in a few transplantation 
centers around the world [10], [13],[14],[15], [16],[17], [18], [19]. 
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Both selective and nonselective antibody removal techniques have been used to reduce 
host anti-A/B antibody titers prior to ABO-incompatible transplantation [20]. The nonselective 
methods include plasma exchange with fresh frozen donor plasma or replacement albumin 
solution and double filtration plasmapheresis [10, 21-23]. Selective antibody removal occurs 
through plasma or whole blood immunoadsorption in packed sorbent columns, containing 
immobilized synthetic A/B-trisaccharide epitopes [13-14, 17, 19, 24-25]. As it appears, the 
outcome of an ABO-incompatible transplantation primarily depends on the peri-transplantation 
anti-A/B antibody titer, and does not correlate with the use of any specific method of antibody 
removal [20]. Nevertheless, nonselective antibody removal techniques have been generally 
associated with higher risks of procedure related complications and morbidities [26-27]. Most of 
the complications have been attributed to the use of donor plasma or replacement albumin 
solution [28]. Total plasma exchange with fresh frozen donor plasma is limited by donor supply 
and is also associated with the risks of infection transmission and immunological reactions to 
non-autologous plasma. Whereas, replacement with albumin solution depletes the recipient of 
requisite proteins, protective immunoglobulins and clotting factors [28]. Plasma 
immunoadsorption requires minimal replacement fluid, but nonetheless, involves the same risks 
associated with plasmapheresis [28]. Direct hemoperfusion through sorbent columns eliminates 
the need for a complicated plasmapheresis procedure, but meanwhile direct contact between 
blood cells and the sorbent material increases the chances of hemolysis and loss of platelets or 
red blood cells [29],[30]. 
Our group previously reported development of a fiber based anti A/B immunosorption 
device (SAF) in which Neutr-AB®, animal based A/B glycoprotein antigens, were covalently 
attached to the luminal surface of hollow fiber membranes [31]. Hollow fibers were perfused 
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with whole blood and the SAF devices selectively removed anti-A/B antibodies in a one step 
process through high affinity interaction between immobilized A or B antigens and the 
corresponding antibodies. Subsequently,  SAF devices  were developed in which synthetic blood 
group A antigens were used as the immobilized ligands [32]. Figure 1-1 shows a schematic of 
antibody removal in the luminal surface of a single fiber in a SAF device. The SAF devices 
present the advantage of eliminating a complicated plasmapheresis procedure [31], [33], [32]. 
Additionally, blood flow through hollow fiber membranes is associated with significantly less 
resistance than blood flow in a sorbent column [34]. Yet, limited surface area for antigen 
immobilization restricts antibody removal capacity of SAF devices and further effort is required 
to enhance the immobilized antigen density [32].     
In this study we had two main objectives: our first objective (as described in detail in 
Chapter 3.0 was to investigate the possibility of enhancing antibody removal capacity of our 
SAF devices by using synthetic blood group A/B trisaccharide antigens conjugated with high 
molecular weight polyacrylamide spacers as the immobilized ligands. We approached this goal 
by performing the following series of studies: 
1.   We conjugated synthetic blood group A/B-trisaccharide epitopes with poly-N 
hydroxyethylacrylamide spacers of 30 and 1000 kDa. The glycopolymers were equipped 
with biotin tags and deposited on streptavidin-coated sensor chips. 
2.   Samples of different clones of IgM monoclonal anti-A antibodies and polyclonal anti-A 
antibodies in plasma were injected over the surface of sensor chips on which glycopolymers 
were immobilized. Using surface plasmon resonance (SPR), the effect of the polyacrylamide 
spacer size (30 kDa or 1000 kDa) on antibody removal capacity of glycopolymers was 
assessed. 
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Figure 1-1: Schematic of the blood perfusion loop and antibody removal in the 
luminal surface of a single fiber in a SAF device. Figure is from the McGowan 
Institute for Regenerative Medicine website. 
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3.   We also assessed the effect of the carbohydrate content (20 mol% or 50 mol%) on antibody 
removal capacity of glycopolymers in their interactions with monoclonal and polyclonal anti-
A antibodies. 
4.   We quantified binding kinetics of Anti-A antibodies to immobilized glycopolymers.  
The results of this study suggested that by immobilization of the high molecular weight (1000 
kD) polyacrylamide glycoconjugates on the luminal surface of hollow fibers in the SAF devices, 
we could potentially achieve a target anti-A antibody titer reduction of three to four titer steps in 
each device. 
Our second objective (as described in detail in Chapters 4.0, 5.0 and 6.0) was to develop 
a new antibody filtering device: Integrated Bead and Fiber Antibody Filter (BSAF). The BSAF 
device contains microfiltration hollow fibers combined with antibody capturing beads uniformly 
distributed within the fiber interstitial space. As blood flows through the fibers, Starling flow 
carries plasma from the inner fiber lumen to the beads in the shell compartment where antibodies 
diffuse and bind to covalently attached polyacrylamide glycoconjugates within the shell-side 
porous beads (Figure 1-2). We envisioned the following advantages for BSAF devices: 
1.  Selectivity in antibody removal: unlike nonselective techniques of antibody removal such as 
plasma exchange, double filtration plasmapheresis or antibody adsorption in protein A 
columns, BSAF devices provide selective antibody removal and do not deplete blood of 
essential proteins, clotting factors or other immunoglobulins.  
2. Compatibility with direct whole blood perfusion: BSAF devices are compatible with whole 
blood perfusion. This simplifies the blood circuit and eliminates the need for a separate 
plasmapheresis unit. 
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Figure 1-2: Schematic of a: an integrated bead and fiber antibody filter (BSAF). b: 
Starling recirculation flow of plasma between the fiber and bead-containing shell 
compartment and antibody removal  in the fiber interstitial space. 
a 
b 
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3. Blood compatibility: there is no direct contact between blood cells and the sorbent material in 
BSAF devices. Therefore, the risks of hemolysis, loss of platelets or red blood cells and other 
biocompatibility concerns associated with a direct contact between blood cells and the 
sorbent material are eliminated.  
4. Fast antibody removal: the sorbent particles in BSAF devices are maintained in suspension. 
Therefore, there is significantly less flow resistance in the fiber interstitial space compared to 
plasma flow in a packed sorbent column. This enables higher flow rates and increases the 
overall antibody removal rate in BSAF devices. 
5. Unlimited antibody removal capacity: antibody removal capacity of BSAF devices is 
practically infinite in relation to the maximum amount of antibodies in blood. Therefore, 
clinically relevant antibody removal rate and capacity can be achieved in one single device. 
This potentially provides a solution to the limited adsorption capacity of our first prototype 
SAF devices. 
6. Consistency in antibody removal: the sorbent particles are maintained in a uniformly 
distributed and well mixed suspension within the fiber interstitial space. Therefore, uniform 
and consistent antibody removal characteristics are expected between devices. Conversely, in 
a sorbent column the particles pack further with fluid flow and time of use [29]. Therefore, 
antibody removal characteristics of the beads change over time and may not be consistent 
between devices.  
7. Simplicity in operation: the same blood circuit in hemodialysis is adaptable for use with 
BSAF devices. Therefore antibody removal in BSAF devices could be performed in clinical 
facilities which are already equipped with hemodialysis machinery. 
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We developed our BSAF devices by performing the following series of studies:  
1.  We developed a mathematical design model that incorporated the mechanisms underlying 
antibody capture in the BSAF and predicted antibody removal rate based on key design and 
operational parameters (Chapter 4.0).  
2. We measured the parameters of our mathematical model and compared key predictions of the 
model with experimental antibody capture data in a series of in-vitro monoclonal anti-A 
antibody capture in BSAF devices packed with anti-A specific beads (Chapter 4.0).  
3. Based on the mathematical model predictions of antibody removal rate in BSAF devices and 
experimental data, we designed a BSAF device that would generate a clinically relevant rate 
of anti-A removal (Chapter 4.0). 
4.  We evaluated the effect of bead mixing on antibody removal rate in BSAF devices. A 
conceptual design for an integrated bead mixing system was proposed. We fabricated 
appropriately scaled down prototypes of our conceptual clinical BSAF device and obtained 
“proof of concept” experimental data in capture of monoclonal anti-A antibodies from buffer 
solution (Chapter 5.0).  
5.  We tested anti-A antibody removal from whole blood in appropriately scaled down 
prototypes of the “clinical” BSAF device and showed that the designed BSAF devices 
effectively and specifically removed anti-A antibodies directly from whole blood (Chapter 
6.0).  
 9 
2.0  BACKGROUND 
2.1 AN OVERVIEW OF IMMUNE RESPONSE TYPES AND MEDIATORS 
Immune responses protect multicellular organisms from potentially harmful invading pathogens 
[36]. Innate immunity is the simplest form of an immune response and utilizes an array of 
primitive and nonspecific defensive tools including physical barriers, toxic molecules and 
phagocytic cells to non-discriminately eliminate pathogens from body [36]. In vertebrates innate 
immunity works in parallel with adaptive immunity, a very sophisticated immune response, 
which utilizes a diverse group of specialized agents to specifically recognize and destroy 
pathogens [36]. Two types of adaptive immune responses are recognized: cellular immunity, 
mediated by T lymphocytes, and humoral immunity, mediated by an enormous collection of 
immunoglobulins, produced by B lymphocytes [37]. Both B and T cell precursors develop from 
the same pluripotent hemopoietic stem cells [36]. In mammals, B cells develop in bone marrow 
and T cells develop in the thymus. Hence both thymus and bone marrow are referred to as central 
or primary lymphoid organs. Mature B and T lymphocytes are transferred to secondary or 
peripheral lymphoid organs including spleen, appendix and lymph nodes [36]. The mature 
lymphocytes continuously recirculate between blood and peripheral lymphoid organs in search 
of antigens [36]. An antigen is any foreign substance (usually a carbohydrate or protein 
structure) that induces the adaptive immune responses. Circulating lymphocytes contain 
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membrane bound receptors with different specificities through which they specifically recognize 
and bind the antigens they encounter. Through this receptor-antigen binding interaction, those 
lymphocytes with specificity for the encountered antigens both proliferate and differentiate. This 
adaptive stimulation of B and T cells is referred to as clonal selection [36].  
The membrane-bound receptors of T cells are composed of two disulfide bonded 
transmembrane polypeptide chains (known as α and β). Each chain is approximately 280 amino 
acids long, containing an amino-terminal variable region and a carboxyl-terminal constant 
region. Two variable amino-terminals cooperate to form a single antigen binding site on the T 
cell receptor [36]. Two general classes of T cells exist: cytotoxic or killer T cells, and helper T 
cells. Cytotoxic T cell receptors specifically recognize antigenic peptides bound to class 1 major 
histocompatibility complex (MHC) molecules (HLA class 1 in human) [36]. Cytotoxic T cell 
receptor-antigen binding interaction leads to release of perforin and granzymes into the antigen 
presenting cells to signal cell apoptosis [36],[6].  Helper T cells specifically recognize peptides 
bound to class 2 MHC molecules (HLA class 2 in human). Although, helper T cells have no 
cytotoxic or phagocytic activity, they play a major role in magnifying immune responses through 
secreting a variety of cytokines which act as local mediators and help activate macrophages, B 
cells and cytotoxic T cells [36],[6].  
The membrane-bound receptors of B cells are specialized glycoproteins called 
immunoglobulins or antibodies.  Once an antibody on the cell surface of a naïve B cell binds a 
specific antigen, the antibody-antigen complex is engulfed and digested by the antibody-bearing 
B cell. The B cell then displays antigenic fragments on the cell surface to elicit T cell stimulation 
and B cell proliferation and differentiation. The B cell progeny, called effecter B cells, secrete 
large amounts of the antigen specific antibodies into blood.  Antibodies specifically bind 
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antigens, employ complement proteins and initiate a cascade of reactions to destroy the antigen 
containing pathogens [36],[6]. A small population of the progeny B cells turns into memory B 
cells which can elicit a secondary and more potent response in a second encounter of the same 
antigen [6]. Each antigen may have several antigenic determinants, called epitopes. Each epitope 
elicits production of a unique antibody with specificity for that epitope. Thus a single antigen 
may activate various clones of B cells, resulting in production of polyclonal antibodies. All 
antibody clones in a polyclonal population bind the same antigen, but antibody-antigen binding 
interactions occur through different antigenic epitopes and affinity of the interactions varies 
[36],[6, 37].  
The simplest antibodies are composed of two identical 23 kDa light (~ 220 amino acids) 
and two identical 53-75 kDa heavy (~440 amino acids) polypeptide chains [37]. Both heavy and 
light chains constitute a variable and a constant region. The constant and variable regions each 
constitute about 110 amino acids [37]. All four chains are associated by disulfide bonds and by 
noncovalent interactions to form a roughly Y shaped symmetric molecule (Figure 2-1). The 
amino-terminus tips of both heavy and light chains in each arm form an antigen binding site. 
Therefore, each Y-shaped antibody has two identical antigen binding sites. The entire light chain 
and the amino-terminal of the heavy chain in each arm is known as a Fab fragment. The 
carboxyl- terminal portion of two heavy chains is known as the Fc fragment [36],[6]. 
 In mammals antibodies are found in five major classes: IgA, IgD, IgE, IgG and IgM, 
distinguished by the differences in their heavy chain compositions known as  α,  δ,  ε,  γ and  µ 
respectively [6],[36].  The amino acid sequence of the constant region of the heavy chain is the 
same between all antibodies in a specific class and subclass. Hence all antibodies of IgM class 
have the µ heavy chain and so forth [37].   
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Figure 2-1: Schematic of an immunoglobulin in the monomeric form. 
 
 
On first exposure to an antigen, the major class of antibodies that is secreted into blood is 
IgM isotype [36]. IgM antibodies are presented in monomeric form as cell-bound receptors and 
in pentameric form containing 5 –four chain units with 10 antigen binding sites when secreted 
into blood (Figure 2-2). The five subunits in an IgM antigen are held together by disulfide 
bonds. A single J chain which is disulfide bonded between two heavy µ chains, conforms IgM 
antibodies into its pentameric structure [37]. IgM antibodies make about 10% of the total 
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immunoglobulins in human blood [36]. They are also the most potent antibody class to activate 
complement system [36],[6], [3]. IgG isotype is the major class of antibodies found in human 
blood and makes up to 75% of total human immunoglobulin concentration [36]. Each IgG 
antibody is composed of one four chained monomer with the heavy chain known as γ chain. This 
isotype is also capable of activating the complement system but is a weaker activator compared 
to IgM isotype [36]. IgG antibodies are produced mainly during the secondary responses.  There 
are four IgG subclasses: IgG1, IgG2, IgG3 and IgG4 with γ1,  γ 2,  γ3 and  γ4  heavy chains, 
respectively [36]. IgG antibodies bind Fc receptors on macrophages and neutrophils and 
facilitate digestion and destruction of antigen coated microorganisms [6]. IgG antibodies are the 
only isotype that cross placenta and are secreted into mother’s milk [36]. IgA is found in body 
secretions including saliva, tears, milk, respiratory and intestinal secretions [36]. IgA is found in 
the form of a four chain monomer in blood and is present as an eight chain dimer in secretions 
(Figure 2-3). IgA antibodies constitute 15% of total human antibody concentration [36]. The last 
two isotypes: IgE and IgD each constitute less than 1% of total antibody concentration. They are 
both found as 4 unit monomers. IgE antibodies bind to receptors on mast cells and basophils and 
induce release of a variety of cytokines and biologically active amines such as histamine. IgD 
antibodies are expressed mainly on mature B cell surfaces and function as antigen receptors. The 
very specific functionality of this class of antibodies is not yet completely understood [36]. 
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Figure 2-2: Schematic of an IgM immunoglobulin in the pentameric form, 
containing 5-four chain units with 10 antigen binding sites. 
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2.2 IMMUNE RESPONSES IN SOLID ORGAN TRANSPLANTATION 
Allograft and xenograft transplantation elicit immune responses in organ recipients due to host 
recognition of “non-self” antigens on the graft cells [3],[38].  Three structurally related antigens 
play the major role in inducing humoral mediated immune responses in solid organ 
transplantation: A, B and α-Gal antigens [39]. In addition to antibody mediated immune 
responses, cellular rejection, accommodation and tolerance are possible immunological reactions 
in solid organ transplantation [39]. In the following section, an overview of the major immune 
responses in solid organ transplantation will be presented.  
2.2.1 Humoral Mediated Rejection in ABO-Incompatible Solid Organ Transplantation 
ABO antigens, also known as histo-blood group antigens, are carbohydrate structures, expressed 
as glycoproteins or glycolipids on almost all cells in the human body [4],[5]. There are three 
antigens in ABO blood group system: A, B and O (H). A and B antigens are characterized by 
two structurally related, but distinct trisaccharides: GalNAcα1−3 [Fucα1−2]Galβ− and 
Galα1−3  [Fucα1−2]Galβ−,    respectivly [5].  
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Figure 2-3: Schematic of an IgA immunoglobulin in dimeric form. 
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The immunodominant sugar structure in O antigen is a disaccharide: [Fucα1−2]Galβ1- 
[5]. The immunodominant sugars of A, B and O antigens are expressed on four different types of 
core saccharide chains [4]: 
Type 1 chain: Galβ1-3GlcNAcβ1-R 
Type 2 chain: Galβ1-4GlcNAcβ1-R 
Type 3 chain: Galβ1-3GalNAcα1-R 
Type 4 chain: Galβ1-3GalNAcβ1-R 
Expression of core saccharide chains and the number of ABO epitopes varies in different 
organs [4]. ABO gene in humans is located on chromosome 9 and encodes synthesis of two 
enzymes: glycosyltransferase A (GTA) and glycosyltransferase B (GTB), which catalyze the 
biosynthetic pathways in synthesis of A and B antigenic determinants, respectively [40]. The 
terminal fucose residue in O antigen provides the basis for synthesis of both A, and B 
trisaccharides [5]. In synthesis of A antigens, GTA transfers the monosaccharide N-
acetylgalactosamine (GalNAc) from the donor substrate (uridine diphosphate- N-
acetylgalactosamine) to fucosylated galactosyl residue of the O antigen. Similarly, in synthesis of 
B antigens, GTB catalyzes transfer of the nucleotide donor uridine diphosphate-galactose to the 
fucosylated galactosyl residue on O antigen [40],[5]. There are four phenotypes in ABO blood 
group system: A, B, AB and O. Blood group A phenotype expresses only A antigens, whereas 
blood group B expresses only B antigens. Individuals of type AB express both A and B antigens 
and type O individuals lack functional glycosyltransferases, hence express neither A nor B 
antigens. Blood group A is divided into two subgroups: A1 and A2 [4]. A1 individuals express a 
larger number of A antigens compared to A2 subjects. Additionally, all four chain types are 
identified in A1 phenotype. Whereas, A2 antigens have only been associated with type 1 and 2 
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chains [4]. Individuals who express ABO antigens on soluble glycoproteins in their body 
secretions are known as secretors [4].  Group A or B non-secretors lack the enzyme α−1,2-
fucosyltransferase type 2 (FUT2) which is responsible for synthesis of H antigen in secretions 
[4]. ABO antigens are expressed on virtually all cells in human body including the vascular 
endothelium, the convoluted distal tubules and the collecting tubules of kidneys, the hepatic 
arteries, portal veins, capillaries, sinusoidal lining cells and bile duct epithelium of liver tissues 
and on the surface of the epicardium and on the vascular endothelium of human heart tissues 
[4],[41].  
According to Landsteiner’s law, humans produce antibodies against those ABO antigens 
that are missing on their tissues [4],[5]. Antigen expression and antibody secretion patterns as 
well as the population distribution of each blood type within ABO blood group system in the 
United States are summarized in Table 2-1. Anti-A and anti-B antibodies are believed to be 
produced in the human body in response to carbohydrate antigens expressed by intestinal 
bacteria [4],[3],[35]. These antibodies bind to A/B antigens due to cross reactivity [4],[3],[5]. 
Anti-A/B antibodies circulate in blood and are predominantly in IgM isotype but are also present 
in the IgG form [42]. 
In ABO-incompatible solid organ transplantation, pre-existing anti-A/B antibodies in the 
organ recipient recognize A/B antigens on the graft endothelium as non-self antigens [6],[3]. 
Antibody-antigen complex formation activates the classical pathway of complement system 
through fixation of C1q (a subunit of C1 protein). Fixation of C1q by at least two antibody Fc 
regions is a crucial complement activation step [3],[43]. Therefore, IgM antibodies which 
provide five Fc regions in close proximity are more potent complement activators than IgG 
isotype [3]. Fixation of C1q by antibodies induces conformational changes in C1q and leads to  
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Table 2-1: Antigen expression, antibody secretion and US population distribution of 
different blood types within ABO blood group system. 
 
 
Blood Type 
(genotype) 
 
Antigen Expression 
(Phenotype) 
 
Antibody Secretion 
(Phenotype) 
 
US Donor 
Percentage 
 
A 
(AA,AO) 
A Anti-B 42% 
   
    B 
(BB,BO) 
B Anti-A 10% 
    
   AB 
(AB) 
A and B None 4% 
     
    O 
(OO) 
O (H) Anti-A and Anti-B 44% 
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activation of the subsequent proteins in the cascade, ultimately resulting in formation of  
membrane attack complexes (MAC) [43]. MAC complexes insert themselves into cell 
membranes and induce cell lysis and endothelial cell disruption [43]. This is followed by platelet 
aggregation, interstitial hemorrhage, edema, and formation of fibrin thrombi [3]. Ultimately, 
rapid swelling of the graft, vascular thrombosis and loss of graft function will occur. This rapid 
and humoral mediated hyperacute graft rejection occurs within 24 hours upon resuming blood 
flow in the transplanted organ [3]. 
Hyperacute organ rejection is the major, but not the only risk factor in ABO-incompatible 
transplantation. Host anti-donor antibodies could also induce acute vascular or accelerated 
cellular rejection. Acute vascular rejection occurs days to months after transplantation [3]. 
Unlike cell-mediated rejection which responds very well to immunosuppressant treatments, 
humoral mediated rejection including: hyper acute, acute vascular and accelerated cell mediated 
rejection are resistant to immunosuppressive therapy [3]. The exact mechanisms underlying 
acute vascular and accelerated cell mediated rejection are yet not completely understood. 
However, both humoral and cell mediated responses are believed to affect these types of 
rejection [3]. 
2.2.2 Humoral Mediated Rejection in Xenotransplantation 
Discordant xenotransplantation without any manipulation of immune system results in hyper 
acute rejection of the graft within minutes to few hours [44],[38]. Hyperacute rejection in 
xenotransplantation is triggered by binding of abundantly produced anti-Gal antibodies to α-Gal 
epitopes (Galα1-3Gal) expressed on pig and other nonprimate mammalian cells [45-46], [39], 
[44]. Anti α−Gal  antibodies are present in human plasma and, similar to anti- A/B antibodies, are 
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produced in  response to  expression of α-Gal epitopes by intestinal bacteria [44]. Current 
research in xenotransplantation is focused on genetically disrupting α1,3 galactosyltransferase 
(α1,3GT) gene in pigs, hence producing pigs which lack α-Gal epitopes [47], [48]. Additionally, 
removal of anti-α-Gal antibodies from circulating blood or depletion of complement proteins 
reduces the risk of hyper acute rejection in xenotransplantation [45], [45, 49],[30, 50-52]. 
However, as anti-α-Gal antibody titers rebound, acute vascular graft rejection occurs in days to 
weeks post transplantation [44],[3].  
2.2.3 Cellular Rejection 
Major histocompatibility complex antigens in humans are known as human leukocyte antigens 
(HLA). Class 1 HLA antigens are found on the surface of most nucleated cells. Class 1 HLA 
antigens present endogenous antigen fragments to cytotoxic T cells upon binding CD8 receptors 
on killer T cells [36].   Class 2 HLA antigens are expressed on most immune cells including 
macrophages, dendritic cells and B cells. These antigens bind CD4 receptors on helper T cells 
and present exogenous antigens to these cells [36]. Cellular organ rejection occurs when donor 
HLA antigens are recognized as foreign substances by host T cells.  Graft cells undergo 
apoptosis via  perforin/ granzyme released by cytotoxic T cells or are subject to lysis via  lytic 
enzymes released by  macrophages [36]. HLA-incompatible transplantation also triggers 
hyperacute rejection in some recipients who are pre-sensitized to donor HLA antigens through  
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blood transfusion, prior transplants or pregnancy [3]. Hyperacute rejection in these cases is 
mediated by pre-exisitng host anti-HLA antibodies which bind HLA antigens and activate 
classical pathway of complement system [3]. Cell-mediated rejection can be prevented or 
reversed by immunosuppressive therapy [3]. 
2.2.4 Accommodation and Tolerance 
Accommodation occurs when a transplanted organ is accepted by recipient as self organ despite 
the existence of anti-donor antibodies in host circulating blood and continued expression of 
foreign antigens on the graft [39],[53-54]. The exact biological pathways leading to 
accommodation are not yet fully understood. Some experimental models in xenotransplantation 
have demonstrated that graft cells undergo genetic changes and produce anti-apoptotic and 
cytoprotective proteins which protect endothelial cells against immunological assaults [53-55]. 
Other studies have demonstrated a decrease in expression of incompatible carbohydrate antigens 
by graft cells and/or production of protective antibodies in the host [55]. Tolerance refers to a 
state of accommodation when host antibodies against donor antigens are suppressed in long term. 
Evidence of tolerance has been observed in ABO-incompatible heart transplantations in infants 
who never produce anti-donor antibodies in long term [56].  
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2.3 PERI-TRANSPLANTATION REMOVAL OF ANTI-DONOR ANTIBODIES IN 
SOLID ORGAN TRANSPLANTATION 
As discussed in the previous section, antigens expressed on donor graft elicit immune responses 
in the transplant recipient. In human allograft transplantation, ABO-incompatibility imposes the 
greatest barrier to solid organ transplantation [4]. However, the number of patients awaiting 
organ transplantation is significantly greater than the number of ABO-compatible donor organs 
that become available [1]. The capability to perform ABO-incompatible transplantation could 
increase the donor pool availability by 30 to 40% [2].   Numerous studies have shown that 
purification of  blood from pre-existing anti-donor antibodies in the peri-transplantation period 
significantly reduces the risk of hyperacute graft rejection in ABO-incompatible transplantation 
[10, 13-15, 17-19, 57-58], [7],  in xenotransplantation [45], [49],[30, 50-52]  and in pre-
sensitized recipients of HLA-incompatible allografts [59],[60]. Additionally studies have shown 
that despite the rebound of anti-A/B titers following the immediate peri-transplantation period,  
accommodation occurs and the risk of humoral mediated organ rejection in ABO-incompatible 
transplantation is reduced to less than 30% [7],[39],[15].  In the next section, a short review of 
prior clinical experiences with allograft ABO-incompatible and HLA-incompatible 
transplantation will be presented. Additionally, a short review of the effect of antibody removal 
in prevention of hyperacute rejection in xenotransplantation will be presented. 
2.3.1 Clinical Experiences in ABO-Incompatible Kidney Transplantation 
Early experiences in ABO-incompatible kidney transplantation in 1950s and 1960s resulted in 
very poor graft survival rates and crossing ABO blood group barrier was considered unsafe for 
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decades [4]. Initially Porter [61] speculated that graft rejection in ABO-incompatible 
transplantation was mediated by binding of anti-A/B antibodies to A/B antigens on the graft 
endothelium [61].  Additionally, by late 1960s, it was already understood that renal grafts from 
A2 blood group individuals expressed A antigens at a much weaker level than A1 individuals 
[62],[4]. Based on these two facts, the first clinical trials in crossing ABO barrier were performed 
by transplanting A2 renal grafts to type O recipients [63]. All 20 patients who participated in this 
study, received a standard immunosuppressive therapy, but did not undergo any other procedure 
for antibody removal. Eight of the kidneys were lost within 1 month, while 12 grafts showed 
long term survival [63]. After this initial successful attempt, several groups adapted the same 
procedure in transplantation of  A2 kidneys to O recipients [64],[65]. Nelson et al. reported a 10-
year large scale study, involving transplantation of A2 and A2B kidneys to B and O patients 
[64]. The acceptable anti-A titer in recipients at the time of transplantation was reported 1:4 titer 
units or below. The reported 2 year graft survival rate was 94% [64]. The first successful large 
scale ABO-incompatible kidney transplantation which included donors other than A2 or A2B 
blood groups was performed by Alexandre et al [8]. This group reported a series of successful 
ABO-incompatible kidney transplantations, following depletion of host blood from anti-A/B 
antibodies using plasma exchange and donor specific platelet transfusion [8]. Six out of nine 
patients showed graft survival for at least 2 to 16 months after transplantation. Following this 
initial successful trial, several other groups adapted an antibody removal procedure and 
demonstrated successful ABO-incompatible organ transplantations with 1-year graft survival 
rates of nearly 90% [7, 10-15, 17-19, 21, 39]. Tanabe et al. showed in a study of 52 end-stage 
renal patients that peri-transplant reduction of anti A/B titers to 1:16 or below resulted in graft 
and patient survival rates of 78 and 91% at 5 years [21]. No significant difference in patient or 
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graft survival rates was observed in ABO-compatible (n=723) versus ABO-incompatible (n=52) 
transplantations [21]. A follow up study of 67 patients over 8 years indicated no significant 
difference in ABO-compatible and ABO-incompatible graft survival rates after year 3. But 
patient survival rate was the same during all 8 years of the study [10]. Other long term survival 
rates have also been very encouraging [10-12]. Ishida et al. [23] reported a 10 year large scale 
study including 101 living related kidney transplantations. In all cases, plasmapheresis and 
immunoadsorption were used to reduce pre-transplantation anti-A/B antibody titers of graft 
recipients to 1:4 or below. Patient survival rate was reported  94% after 1 year and 92% after 5 
years. Graft survival rate was 76% after 1 year and 73% after 5 years. The same study indicated 
that 75% of patients showed no increase in anti-A/B titers following transplantation [23]. Graft 
loss was only observed in 12% of patients, 9% of which lost grafts within 2 months and 4% lost 
grafts within a year. Graft loss was observed in all patients who had postoperative anti-donor 
titers of 1:64 or higher [23].  Toma et al. reviewed long term patient and graft survival rates in 
213 patients who underwent ABO-incompatible renal transplantation at 41 centers in Japan 
between January 1989 and 1998. Antibody titers were reduced to 1:16 or lower through several 
sessions of plasma exchange, double filtration plasmapheresis or plasma immunoadsorption. 
Patient and graft survival rates were reported to be 91% and 82% at 1 year and 75% and 57% at 
9 years, respectively [12]. No significant difference in patient or graft survival rates were 
observed between ABO-compatible and ABO-cross matched transplantations [12]. 
2.3.2 Clinical Attempts in ABO-Incompatible Liver Transplantation 
ABO-incompatible liver transplantation has been performed only in emergency cases of hepatic 
failure, when the only organ available has been ABO-incompatible [4]. ABO-incompatible liver 
 26 
transplantation rarely results in hyper acute rejection. However, graft survival rates are poor and 
liver transplants fail due to vascular thrombosis and bile duct complications [4]. Gordon et al. 
[66] reported a series of 672 liver transplants in 1986, with a 3 year graft survival rate of 56% in 
520 ABO-identical grafts, 39% in 91 ABO-compatible and 36% in 31 ABO-incompatible liver 
transplants [66],[4]. Fifteen cases of ABO-incompatible liver transplantation were reported from 
the Mayo clinic with a 1 year patient and graft survival rates of 57 and 46%, respectively [67].  
Mor et al. reported a study in which preoperative plasmapheresis was used to reduce  anti- A/B 
titers to 1:16 or below in 10 patients undergoing ABO-incompatible liver transplantation. Patient  
and graft survival rates were 80% and 60%, respectively  at a follow up time of 5-17 months 
[16]. Hanto et al. used double volume plasma exchange in 14 cases of ABO-incompatible liver 
transplantation, and reported 1 year graft survival rate of 71.4% [15]. No immunological graft 
losses were observed in any of the cases [15]. Skogsberg et al reported results of ABO-
incompatible cadaveric liver transplantation in 12 blood group O adult patients [18]. No pre-
operative plasmapheresis was performed but three patients underwent plasmapheresis post 
transplantation [18]. Patient and graft survival rates were 83% and 67%, respectively, with a 6.5 
month follow up median [18]. Slightly better graft survival rates have been observed in pediatric 
liver transplantation. Tanaka et al reported patient and graft survival rates of 77% in a series of 
13 pediatric ABO-incompatible related living kidney transplantations [68]. In a report published 
by Varela-Fascinetto et al, the 10 year patient and graft survival rate in 28 ABO-incompatible 
liver transplantations was 71% and 67%, respectively. No significant difference in ABO-
incompatible, ABO-compatible or ABO-identical liver transplantations  was observed [69]. 
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2.3.3 Clinical Attempts in ABO-Incompatible Heart and Lung  Transplantation 
Very few cases of ABO-incompatible heart and/or lung transplantation have been reported and 
the success rates have been generally very low. A series of ABO-incompatible heart 
transplantation in small children were reported by West et al. which used plasma exchange 
during cardiopulmonary bypass [56]. Seven out of 10 transplanted grafts survived in a follow up 
time of 11 months to 4.6 years. Pierson et al. reported the first successful ABO-mismatch lung 
transplantation, following inadvertent transplantation of type A lung to a type B patient [70]. 
Following rebound of anti-A titers, patient underwent plasmapheresis and plasma 
immunoadsorption. Patient was reported “clinically well” three years after transplantation. 
Recently, Struber et al reported one intentional case of transplantation of a lung from a deceased 
type AB donor to type O recipient. Anti-A/B antibodies were removed from circulating blood by 
plasmapheresis and immunoadsorption. The patient was reported well and at home at nine 
months follow up [71]. 
2.3.4 Clinical Attempts in HLA-Incompatible Allograft Transplantation 
Anti-human leukocyte antigen (HLA) antibodies are produced in pre-sensitized patients mainly 
due to prior pregnancy, repeated blood transfusions or chronic dialysis [3]. Renal and cardiac 
HLA-incompatible transplantation results in a high rate of hyperacute rejection and graft loss 
following binding of recipient anti-HLA antibodies to donor HLA antigens. Pre-transplantation 
removal of recipient anti-HLA antibodies is performed by plasma exchange or by plasma 
immunoadsorption through protein A columns with relatively high success rates. In a study of 
eighteen HLA-incompatible kidney transplantations, Sonnenday et al. removed anti-donor HLA 
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antibodies in an average of three plasma exchange sessions and reported 94% graft survival rate 
at 1 to 44 months post transplant [60]. Ross et al. removed anti-HLA antibodies through plasma 
immunoadsorption in protein A columns and reported 80% graft survival rate for 3 to 34 months 
post transplant [59].  
2.3.5 Clinical Attempts in Xenotransplantation  
The major barrier to successful xenotransplantation is binding of natural anti-α-Gal antibodies to 
Galα1-3Gal (α-Gal) antigenic determinants expressed abundantly on nonprimate mammalian 
grafts [72],[73],[45-46, 74]. These naturally occurring antibodies mediate hyperacute and acute 
rejection of nonprimate mammalian grafts transplanted into primates.  Pre-transplantation 
removal of anti-α-Gal antibodies through plasma exchange or immunoadsorption through 
beaded columns containing α-Gal oligosaccharides significantly reduces the risk of hyperacute 
rejection [45],[49],[30, 50-52]. However, rapid rebound of anti-α-Gal antibody titers results in 
delayed humoral rejection. In an in-vivo study, Taniguchi et al. showed that serum anti-α-Gal 
antibodies were reduced significantly in baboons following plasma immunoadsorption in 
columns containing macroporous glass beads, on which polyacrylamide-synthetic Gal conjugates 
were immobilized [51]. Although both IgM and IgG anti-α-Gal antibody titers were significantly 
reduced, antibody titers rebound within a week following the last immunoadsorption session 
[51]. Kozlowski et al. showed in a series of in-vivo baboon plasma perfusion through 
immunoaffinity columns that both IgM and IgG anti-α-Gal antibody titers were reduced by 81-
97% immediately after immunoadsorption. However, the antibody titers rapidly rebound to the 
pre-immunoadsorption levels within 1-6 days [52]. Following perfusion of separated plasma or 
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whole blood through immunoadsorbent columns containing α-Gal epitopes, Xu et al 
demonstrated that removal of anti-α-Gal antibodies from blood was sufficient to prevent 
hyperacute rejection of a transplanted pig kidney [30]. The same study also indicated that 
perfusion of whole blood through beaded columns was associated with a 30% decrease in 
hematocrit and 40-50% decrease in platelet count [30]. A combination of hemodilution and 
nonspecific removal of red blood cells was reported responsible for the decrease in hematocrit. 
Hemoperfusion also resulted in transient reduction in total immunoglobulin, platelet, 
complement, total protein, albumin and fibrinogen concentrations due to hemodilution [30]. 
Despite the success in complete removal of anti-α-Gal antibodies in immunoadsorption columns 
prior to xenotransplantation, delayed antibody mediated rejection following rebound of anti-α-
Gal antibodies remains an obstacle in xenotransplantation. Current efforts in this area are 
directed towards production of transgenic pigs which do not express α-Gal antigens [47-48],[75], 
hence eliminating the need for removal of anti-α-Gal antibodies. 
2.4 ANTIBODY REMOVAL TECHNIQUES 
As discussed in the previous section, antibody removal is performed to prevent hyperacute 
rejection in ABO-incompatible organ transplantation [8, 10, 22],[21, 71], in xenotransplantation 
[30, 51, 76-78] and in HLA-incompatible allograft transplantation in pre-sensitized organ 
recipients [60], [59]. Additionally antibody removal is used in treatment of many autoimmune  
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diseases [79],[80],[81],[82]. Both selective and nonselective techniques of antibody removal 
have been used previously. In the following section, a short overview of each of these techniques 
will be presented.  
2.4.1 Plasmapheresis or Therapeutic Plasma Exchange  
In plasmapheresis or therapeutic plasma exchange, plasma is separated from blood cells and is 
replaced with either fresh frozen donor plasma or 5% albumin solution [28],[83]. Plasma 
exchange is used for fast removal of the factors that associate with certain diseases 
[83],[79],[81]. Examples include removal of  pathogenic autoantibodies which mediate 
autoimmune diseases, immune complexes, thrombotic factors and cholesterol containing 
lipoproteins [83],[79]. Plasmapheresis is also used to remove high and middle molecular weight 
blood proteins that participate in the inflammatory processes such as activated complement 
products, fibrinogen and possibly cytokines [83]. Other examples include removal of anti-A/B 
[8, 10, 22],[21, 71], [56], [18], [84],  anti-HLA [60] and anti-α-Gal antibodies [85],[77] to 
facilitate ABO-incompatible, HLA- incompatible or xenotransplantation.  
Therapeutic plasmapheresis is performed either by centrifugation or by membrane 
filtration [83]. A centrifugal plasmapheresis device typically consists of a bell shaped bowl 
which rotates at about 16000 rpm [28]. Venous blood is withdrawn from patient and is pumped 
into the device at a typical flow rate of 100 ml/min [28]. Blood cells and plasma are separated 
due to centrifugal forces and plasma is removed through a central outlet port on top of the bowl. 
Each cycle has to be disrupted once the bowl is full of red blood cells. The packed blood cells 
will be collected and returned to patient after addition of substitution fluid [28],[83]. Each cycle 
usually removes approximately 400 to 700 ml of plasma [28]. Continuous flow and intermittent 
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centrifugation are similar in principles. However, in the continuous process, there are outlet ports 
for simultaneous removal of both plasma and blood cells [83]. The extracorporeal volume is 
smaller (220 to 350 ml) in the continuous flow centrifugation. Therefore, this type of 
plasmapheresis is more appropriate for treatment of patients with severe anemia or 
cardiovascular impairment [83], [28]. In a continuous flow centrifuge, approximately 3L of 
plasma can be removed within 90 minutes [86].  
Membrane based filters contain microfiltration hollow fibers with pore sizes ranging 
between 0.2 and 0.77 µm [83],[28]. In these devices blood cells are separated from plasma due to 
transmembrane pressure. The maximum limit for transmembrane pressure is typically 70-100 
mm-Hg, due to the risk of fiber rupture [28]. The optimal blood flow rate for plasma filtration is 
usually 100 ± 20 ml/min and the filtration flow rate is typically 15-50 ml/min [28].  The 
optimum filtration flow rate is determined based on the filtration characteristics of the fibers. 
Usually as filtration flow rate exceeds a certain range, the plasmapheresis yield declines due to 
the increased rate of fiber fouling [28].  
Total plasma exchange with fresh frozen donor plasma is limited by donor supply and is 
also associated with the risks of infection transmission and immunological reactions to non-
autologous plasma [28]. The risk factor associated with the use of 5% albumin solution as the 
replacement fluid is depletion of blood from the requisite proteins, such as clotting factors, 
platelets, and immunoglobulins [28].  
2.4.2 Double Filtration Plasmapheresis 
Double filtration plasmapheresis provides semi-selectivity in removal of target molecules from 
blood. In double filtration plasmapheresis, two membrane based plasmapheresis devices with 
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different pore sizes are used successively. Blood cells are separated from plasma in the first filter 
with a pore size of approximately 0.2 µm. Plasma is then passed through a second filter whose 
pore size is 0.03 µm [83],[87]. Cleared plasma is recombined with blood cells and returns to 
patient. Total amount of discarded plasma is 500-600 ml. Therefore minimal replacement fluid is 
required [87]. Inlet blood flow rate is typically 50-100 ml/min and approximately 3-4 L of 
plasma is obtained over 2-3 hours [87]. Double filtration plasmapheresis is used in a limited 
number of transplantation centers to remove anti-A/B antibodies in ABO-incompatible 
transplantation [12],[23]. 
2.4.3 Protein-A Columns 
Protein A columns provide the advantage of semi-selective  removal of plasma immunoglobulins 
[80],[82]. Antibody removal in protein-A columns is preferred over nonselective antibody 
removal techniques, such as plasmapheresis, as no replacement solution is required. However 
protective immunoglobulins, other than the targeted pathogenic antibodies, are also removed in 
this process. Two protein-A containing columns: Prosorba® and Immunosorba® are currently 
FDA-approved and are used in treatment of rheumatoid arthritis, idiopathic thrombocytopenic 
purpura and hemophilia with inhibitors [80], [82], [88]. In Prosorba® columns, protein A is 
immobilized on silica beads. Immunosorba® columns contain protein-A, covalently attached 
within the pores of Sepharose particles. Both columns are commercially available through 
Fresenius Hemocare (Redmond, WA). 
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2.4.4 Selective Bead-Based Immunoadsorption 
Immunoadsorption columns have been developed to selectively remove antibodies from whole 
blood or plasma. These columns typically contain porous beads within the pores of  which 
antigens with affinity for the target antibodies are immobilized [89],[24],[25],[30]. Biosynsorb® 
from Chembiomed (Alberta, Canada) [90], BioSorbent A and B developed by Rieben et al. [24] 
and Glycosorb® from Glycorex transplantation AB (Lund, Sweden) [25] are  affinity columns 
specifically made for removing anti-A/B antibodies from human plasma or whole blood. 
Biosynsorb® columns were previously available but are no longer in the market [90],[89]. These 
columns contained synthetic A or B antigens immobilized on silica beads [90]. The bead also 
contained a thin coating of polystyrene which made them compatible with whole blood perfusion 
[90]. Nonetheless, significant loss of hematocrit and platelet count was observed in some studies 
during perfusion of whole blood through these columns [30]. In BioSorbent A and B columns, 
synthetic A or B –trisacchsride antigens were conjugated with poly-N hydroxyethylacrylamide 
spacers and were covalently attached to macroporous glass beads with a pore diameter of 200 nm 
[24].  Currently, only Glycosorb columns are commercially available through Glycorex 
transplantation AB (Lund, Sweden). In Glycosorb columns, synthetic A or B antigens are 
conjugated via short aliphatic hydrocarbon chains (up to 6 carbon atoms in length) within the 
pores of Sepharose particles [25]. Glycosorb columns are approved for human clinical use is 
Europe and have been used to reduce anti-A/B antibody titers to 1:8 or below in ABO-
incompatible kidney, liver and lung transplantation [13],[19-20],[91],[14, 17, 70, 92-97]. 
Similarly affinity columns for removal of anti-α-Gal antibodies have been developed and 
used in in-vitro and in-vivo [30, 51, 76-78] studies to remove anti-α-Gal antibodies in baboons. 
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Taniguchi et al. developed immunoadsorption columns for specific removal of anti-α-Gal  
antibodies by immobilizing  spacered α-galactose disaccharide conjugated with  poly-N 
hydroxyethylacrylamide to macroporous glass beads [51]. Xu et al. developed affinity columns 
by immobilizing two types of α-Gal trisaccharides on silica beads and demonstrated that type 6 
α-Gal trisaccharides were more efficient in removing anti-α-Gal antibodies. Efficiency of 
antibody removal and safety of these columns were later confirmed in a large scale study [76].  
Immunoadsorption columns offer the advantage of specifically removing the target 
antibodies. Nonetheless, in most cases a complicated plasmapheresis procedure is coupled with 
immunoadsorption to eliminate any risks associated with direct contact of blood cells with the 
immunoadsorbent material [13],[19-20],[91],[14, 17, 70, 92-97]. The risks associated with 
plasmapheresis include haemodynamic and cardiovascular complications [28]. Conversely, the 
adverse effects of direct hemoperfusion through columns usually include loss of platelets, 
decrease in hematocrit, increase in coagulation time and electrolyte imbalances [29-30]. In some 
cases the  beads have been coated with a biocompatible polymer to make them compatible with 
direct hemoperfusion [90]. However, the coating significantly reduces the removal capacity of 
the beads and may not completely eliminate all the risk factors associated with  direct 
hemoperfusion through columns [30]. Additionally, there are a number of practical and safety 
difficulties associated with the use of sorbent columns [29]. Most sorbent columns are 
compressible and cause a large pressure drop across the columns. The smaller the beads are, the 
greater the cost of pressure drop will be. Therefore, blood flow rate has to be maintained at a 
typically low range (10-20 ml/min) to maintain pressure drop in a manageable range [29]. In 
practical terms,  the size of the beads in columns can not be smaller than 20-50 µm as pressure 
drop across the column length for smaller beads becomes unmanageable [29].  
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2.4.5 Selective Fiber-Based Immunoadsorption 
Similar to affinity columns, the fiber based immunoadsorption devices use immobilized ligands 
with specific affinity for the target antibodies. However, in fiber based immunoadsorption, 
antigens are directly immobilized on the inner, outer or internal surfaces of dialysis or 
microfiltration fibers. Several groups have developed fiber based immunoadsorption devices for 
removal of target antibodies from blood or plasma [31],[33],[32, 98-99]. Our own group 
previously developed specific antibody filtering devices (SAF) designed for removal of 
antibodies directly from whole blood without the need for prior plasmapheresis [31-33]. In these 
devices, ligands specific to the targeted antibodies were immobilized on the luminal surfaces of 
dialyzer fibers potted into modules. Whole blood perfusion through the fibers resulted in 
antibody capture at the fiber walls (Figure 1-1).  The first predecessor SAF was fabricated and 
tested by Hout et al. [31]. This device incorporated Neutr-AB®, an animal based A and B 
glycoprotein antigen, immobilized on the lumenal surfaces of modified Hemophan® dialysis 
fibers. Bench-top experiments demonstrated that anti-A and anti-B titers of average to high titer 
type O blood could be reduced to 1:2 or below from 300-400 ml of whole blood recirculating 
through this device [31]. Purification of Neutr-AB prior to immobilization to remove a lower 
molecular weight non-antigenic fraction further increased the apparent binding capacity of the 
predecessor SAF by six fold [31]. Based on these preliminary results, it was estimated that two to 
three dialyzers modified with purified Neutr-AB were required to significantly reduce anti-A/B 
antibody titers in 3-5 L of blood [31]. Gautam et al. developed a SAF device for removal of anti-
A antibodies which used synthetic blood group A-trisaccharide antigens conjugated to 
polyacrylamide spacers as the immobilized ligands [32]. Using a mathematical model of 
antibody removal and in vitro anti-A capture data obtained in appropriately scaled down 
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modules, these studies indicated that a minimum antibody binding capacity of 0.0045 nmol/cm2 
would be required for a clinically effective device. This removal capacity was 5 to 6 fold higher 
than the antibody binding capacity achieved based on current immobilization methods [32] . As 
we will discuss in more detail, efforts have been ongoing to increase antibody removal capacity 
of the SAF modules by using high molecular weight spacers and by increasing the surface area 
for antigen immobilization through use of  fibers with larger pore sizes [100].  
2.5 INTEGRATED FIBER AND BEAD ANTIBODY FILTERS (BSAF) 
2.5.1 Integrated Sorbent Suspension/Fiber Devices 
Integrated sorbent suspension/fiber is referred to a class of blood detoxification devices in which 
sorbent particles are suspended in the interstitial space of microfiltration fibers and rely on 
Starling recirculation flow of plasma between the fiber and the bead-containing shell 
compartment to  transfer target molecules from blood to the sorbent material (similar to our 
BSAF devices). Previously Falkenhagen and his group developed microspheres-based 
detoxification system (MDS), for blood detoxification in liver failure and sepsis [101-107]. In 
MDS the dialysate side of a standard plasma filter is combined with a secondary extracorporeal 
flow loop in which adsorbent particles are suspended. The volume of this secondary loop is 
approximately 300 ml per 1 L of processed blood [104] . Blood flow rate is typically 200 ml/min 
and the bead suspension flow rate is 4-6 L/min [102, 104]. Weber et al. immobilized anti-TNF 
antibodies on cellulose beads (1-10 µm) and used these beads in MDS to remove TNF from 
human plasma [104, 107]. The same group has also applied a combination of a hydrophobic 
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neutral resin and an anion exchange resin as sorbent material in MDS to remove albumin-bound 
substances such as unconjugated birilubin or cholic acid and non protein-bound substances such 
as phenol from blood [101]. Overall, the efficacy of MDS in removal of small and middle 
molecular weight blood proteins such as endotoxins, digitoxin, unconjugated birilubin and 
tryptophan has been shown in several publications [101-108]. 
The suspended sorbent particles in integrated sorbent suspension/ fiber devices cause 
significantly less flow resistance in the fiber interstitial space compared to plasma flow in a 
packed sorbent column. As a result, flow rate in the fiber interstitial space can be up to 10-fold 
higher than blood/plasma flow rate in a packed sorbent column. Additionally as pressure drop is 
much smaller along the length of the modules, smaller beads can be used in sorbent 
suspension/fiber devices [29]. All this increases the overall removal rate and capacity of these 
devices. The upper limit for blood flow rate is mainly dictated by hemodynamic stability of 
patient as well as the capability of fibers to withstand transmembrane pressure at the given flow 
rate [29]. Typically blood flow rate in the range of 100-500 ml/min may be applied.  The lower 
limit of the bead size is dictated by the size of the fiber pores. 
2.5.2 BSAF Devices for Specific Removal of Anti-A/B Antibodies from Blood 
A new class of antibody removal devices, the integrated bead and fiber specific antibody filters 
(BSAF), are under development in out laboratory,. BSAF devices are composed of 
microfiltration hollow fibers, potted into modules with immunoadsorbent beads uniformly 
distributed in suspension within the fiber interstitial space (Figure 1-2). The blood perfusion 
loop in BSAF devices is similar to the perfusion loop used in our first prototype SAF devices 
(Figure 1-1). Antibody removal in BSAF occurs as a result of Starling recirculation flow 
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between the fibers and the shell compartment, along with antibody diffusing and binding to 
novel synthetic antigens, immobilized within the shell side porous beads. As we will discuss in 
detail in the following chapters, we have developed a mathematical model to quantify antibody 
adsorption rate in BSAF devices as a function of key design and operational parameters. We 
have validated the mathematical model in appropriately scaled down capture system of 
monoclonal anti-A antibodies in physiological buffer solution . We used this model to design full 
scale BSAF devices and showed in our studies that appropriately scaled down prototypes of our 
designed BSAF modules are capable of depleting up to 100% of reservoir anti-A antibody 
concentration within two hours from buffer and whole blood. A list of potential advantages of 
antibody removal in BSAF devices was presented in Chapter 1.0. One major challenge in 
development of full scale BSAF devices is to integrate a bead mixing mechanism within the 
device to maintain the bead slurry in a continuously mixed condition. In the following chapters 
we will discuss the theoretical and experimental studies performed to develop BSAF devices for 
antibody removal from whole blood and we will further discuss our envisioned design of an 
integrated bead mixing mechanism for our BSAF devices.  
Our first prototype BSAF modules were developed for removal of anti-A antibodies due 
to the widespread clinical application of anti-A removal in ABO-incompatible transplantation 
(see Table 2-1). However, as mentioned in the previous section, antibody removal is required in 
various other clinical applications. Therefore, the same approach could be easily applied to 
develop BSAF devices for specific removal of other pathogenic antibodies. Additionally, the 
work presented here will provide a basis to design other blood purification devices which aim at 
removal of toxins from blood. Examples of such applications are in treatment of 
hypercholesterolemia, liver failure and  sepsis  [88, 109-110]. 
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3.0  ANALYSIS OF BINDING INTERACTIONS BETWEEN A- TRISACCHARIDE-
POLYACRYLAMIDE GLYCOCONJUGATES AND ANTI-A ANTIBODIES USING 
SURFACE PLASMON RESONANCE TECHNOLOGY 
As discussed in chapter 2.0, specific immunoadsorption of anti-A/B antibodies from plasma or 
whole blood provides a superior alternative to nonselective or semi-selective antibody removal 
techniques, since only anti-A/B antibodies are removed from plasma and minimal replacement 
fluid is required. Our group has been developing fiber based anti-A/B immunoadsorption 
devices, designed for specific removal of blood group antibodies directly from whole blood, 
without the need for prior plasmapheresis [31-33, 100]. In chapter 2.0, we described 
development of our first specific antibody filters (SAF), which were composed of dialyzer 
hollow fiber membranes potted into cartridges, with blood group A or B antigens covalently 
attached on the luminal surfaces of the fibers [31-32]. Initially, an animal based A and B 
glycoprotein antigen (Neutr-AB®) was used as the immunoadsorbent material in our SAF 
devices [31]. Antibody capture in Neutr-AB® -based SAF devices resulted in reduction of  anti-A 
and anti-B titers of 300-400 ml of type O blood by 75-98% [31]. Purification of Neutr-AB prior 
to immobilization  to remove a lower molecular weight non-antigenic fraction further increased 
the binding capacity by six fold [31]. However, the SAF antibody removal capacity was still 
significantly lower than the required level for a clinically effective device [31]. In an effort to 
further improve both antibody removal capacity and biocompatibility of SAF devices, Gautam et 
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al. used synthetic blood group A-trisaccharide antigens conjugated to 30 kDa poly N-
hydroxyethylacrylamide  spacers (Atri-PAA30) as the immobilized ligands in the SAF device 
[32]. Using a mathematical model of antibody removal and in-vitro anti-A antibody capture data 
obtained in appropriately scaled down modules, these studies indicated that a minimum antibody 
binding capacity of 0.0045 nmol/cm2 would be required for a clinically effective device [32]. 
This level of immobilized antigen is 5 to 6 fold higher than the antibody binding capacity 
achieved based on our current immobilization methods. 
In this study, we conjugated blood group A-trisaccharide antigens to high molecular 
weight (1000-2000 kDa) poly N-hydroxyethylacrylamide spacers (Atri-PAA1000). This new, high 
molecular weight glycoconjugate was investigated as an alternative synthetic A antigen for 
antibody removal devices. The glycopolymers equipped with biotin tags (Atri-PAA30-biotin and 
Atri-PAA1000-biotin) were deposited on streptavidin coated sensor chips and the affinity and 
kinetics of anti-A antibodies binding to these glycoconjugates were studied using surface 
plasmon resonance (SPR).  Antibody removal capacity of the high molecular weight 
glycoconjugate (Atri-PAA1000-biotin)-immobilized surface was 2-3 times higher than with the 
low molecular weight glycoconjugate (Atri-PAA30-biotin) immobilized surface. The 
carbohydrate content in Atri-PAA1000-biotin (20 mol% or 50 mol %) did not affect antibody 
binding capacity of the glycoconjugate. To assess the strength of the binding interactions, the 
kinetics and affinities in interactions between several clones of anti-A antibodies and (Atri-
PAA1000-biotin) were measured and compared to reference values for monoclonal antibody- 
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antigen interactions. The results suggest that anti-A/B immunoadsorption devices, especially 
hollow fiber-based antibody filters which are limited in surface area for antigen immobilization, 
may greatly benefit from the new synthetic high molecular weight polyacrylamide 
glycoconjugates. 
3.1 MATERIALS AND METHODS 
3.1.1 Instrumentation 
All experiments were performed using a Biacore® 3000 optical biosensor (Biacore AB, Uppsala, 
Sweden), equipped with research grade streptavidin-coated sensor chips (SA) (Biacore AB, 
Uppsala, Sweden). The temperature of the instrument was set at 25oC and data were collected at 
a collection rate of 5 Hz. The Biacore instrument uses surface plasmon resonance technology 
(SPR) to quantitatively measure the rate of binding of a soluble ligand to an immobilized binding 
partner in real time [111]. The SPR signal is expressed in resonance units (RU) and is a measure 
of mass concentration at the sensor chip surface [111]. . A satisfactory linear relationship has 
been found between resonance units and surface concentration of proteins, sugars and DNA 
[111]. This technology has been used for measurement of the kinetic rate constants, as well as 
the equilibrium constants in biomolecular interactions [112] [113] [114]. 
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3.1.2 Reagents 
All reagents and chemicals were obtained from Biacore AB (Uppsala, Sweden) unless otherwise 
specified. Filtered and degassed HBS-EP buffer at pH 7.4 contained 0.01 M N-2-hydroxyethyl-
piperazine-N’-2-ethanesulfonic acid (HEPES), 0.15 M sodium chloride (NaCl), 3 mM 
ethylenediaminetetraacetic acid (EDTA) and 0.005% polysorbate-20 (v/v). HBS-N buffer 
contained 0.01 M HEPES and 0.15 M  NaCl, at pH 7.4. 
3.1.3 Monoclonal Anti-A Antibodies  
Murine monoclonal anti-A antibodies were all of immunoglobulin M (IgM) class; Clone F98 
7C6-4 (401 µg/ml) was obtained from Dominion Biologicals, Ltd. (Dartmouth, NS, Canada), 
Clone A-16 (37 µg/ml) was from Hematological Center (Moscow, Russia), and the Anti-A 
series1 (47 µg/ml) was from Immucor Inc. (Norcross, GA, USA). The stock concentration of 
each of the monoclonal antibodies was measured by enzyme linked immunosorbent assay 
(ELISA) as described previously [116]. 
3.1.4 Plasma  
Samples of fresh frozen plasma type B from three different healthy donors were obtained from 
the Central Blood Bank of Pittsburgh. Blood typing and measurement of anti-A/B antibody titers 
were performed according to the standard blood bank procedure for hemagglutination assay 
[117]. Briefly, plasma samples were serially diluted in 0.9% Saline solution. One drop of either 
A1 or B reference red blood cells (Immucore Inc., Norcross, GA, USA) was added to each tube 
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and tubes were centrifuged for 1 minute at 3300 rpm. Tubes were then examined for 
agglutination of A1 and B red blood cells. Anti-A and anti-B titers were recorded as the 
reciprocal of the largest dilutions that agglutinated A1 and B reference blood cells, respectively. 
As expected for type B plasma, all three samples agglutinated type A but not type B blood cells. 
Anti-A antibody titer in plasma samples (#2) and (#3) were 16 and in sample (#1) the measured 
titer was 32.  
3.1.5 Synthesis of Polyacrylamide Glycoconjugates 
All polyacrylamide glycoconjugates were synthesized at Shemyakin and Ovchinnikov Institute 
of Bioorganic Chemistry (Russian Academy of Sciences, Moscow, Russia). Specific determinant 
fragments of blood group A-trisaccharide antigen (Atri),  GalNAcα1−3[Fucα1−2]Galβ−, and B-
trisaccharide antigen (Btri), Galα1−3[Fucα1−2]Galβ−, were synthesized as ω-aminopropyl 
glycosides as previously described [119].  30 kDa poly(4-nitrophenyl acrylate) (pNPA30) and 
1000 kDa poly(N-oxysuccinimidyl acrylate) (pNSA1000) were synthesized as previously 
described [120-121]. The glycoconjugates containing 20 or 50 mol % of the A or B -
trisaccharides and 5 mol% of biotin were also prepared according to the previously described 
method [120]. Briefly, aminopropyl glycosides (2 or 5 mmol) and biotin-NH(CH2)6NH2 (0.5 
mmol) were added to a solution of 10 mmol activated polymer (pNPA30 or pNSA1000) in 
dimethyl sulfoxide (DMSO). The reaction mixture was kept at 40oC for 24 hours. The exhaustive 
immobilization of the aminoligands to the polymers was confirmed by thin layer 
chromatography (TLC). The remaining active ester groups in the polymer were quenched by 
treatment with ethanolamine. The synthesized glycoconjugates were purified by gel-permeation 
chromatography.  
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3.1.6 Immobilization of Synthetic Antigens on SA Sensor Chips 
Flow cells of SA sensor chips were primed with running buffer (HBS-EP), followed by three 
consecutive injections of 90 µl of 1 M  NaCl in 40 mM sodium hydroxide (NaOH) at a flow rate 
of 90 µl/min. The immobilization protocol varied slightly for kinetic and binding capacity 
studies. In binding capacity experiments, antigens were immobilized at maximum surface 
loading capacity, which ensured that antibody removal was not limited by the amount of 
immobilized antigens on the surface. Glycoconjugate solution (5 µg/ml in HBS-N buffer) was 
injected over the surface at a flow rate of 2 µl/min until a plateau in the binding curve was 
observed, signifying that equilibrium had been reached. This typically happened within five 
minutes of sample injection. Repeated injections of the glycoconjugate solution after reaching 
equilibrium did not increase the surface loading density.  For kinetic studies, a low level of 
antigen loading was desired to minimize the effect of diffusion limitation on the kinetic analysis 
[122]. Immobilization was performed by injecting 5 µl of the glycoconjugate solution (1 µg/ml 
in HBS-N buffer) over the specified flow cells at a flow rate of 2 µl/min. The amount of 
glycoconjugates immobilized on each surface was quantified by subtracting the baseline 
response level of the glycoconjugate solution before the injection from the baseline level after 
injection. Thus variations of synthetic A antigens (Atri-PAA1000-biotin or Atri-PAA30-biotin) 
were immobilized on test sensor chips. Control surfaces for measurement of non-specific binding 
levels included immobilized synthetic B antigens (Btri-PAA1000-biotin or Btri-PAA30-biotin) or 
immobilized spacers (PAA1000-biotin).   
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3.1.7 Measurement of Anti-A Antibody Removal Capacity of Immobilized Antigens  
Samples of different clones of IgM monoclonal anti-A antibodies (A16, Anti-A series1 and F98 
7C6-4) were diluted to one-half their original stock concentrations in HBS-EP buffer. Each 
sample was then injected at a flow rate of 20 µl/min over the surface of a sensor chip specifically 
prepared for binding capacity studies. Each injection was continued until a plateau in the 
response sensogram indicated that equilibrium was reached. After injections, the surfaces were 
regenerated by a single 30 second injection of 50mM NaOH solution and consequently, 
monoclonal antibody samples, diluted to 75% of their original concentrations were injected over 
regenerated surfaces. Similar binding levels of monoclonal antibodies diluted to 50% and 75% 
their original concentrations ensured that the reported binding levels represented the maximum 
surface removal capacity for a given antibody.  Similarly, polyclonal anti-A antibodies in plasma 
type B were injected over sensor chips. Unlike monoclonal antibodies, we did not dilute plasma 
samples because initial measurement of anti-A antibody titer in plasma samples indicated several 
folds lower antibody concentrations in plasma samples compared to the stock solution of 
monoclonal antibodies. Anti-A antibody removal capacity of immobilized antigens in each case 
was considered to be the equilibrium binding level in resonance units (RU). All surfaces were 
regenerated, by a single 30 second injection of 50mM NaOH solution at a flow rate of 90 µl/min 
to remove bound monoclonal or plasma antibodies. This regeneration protocol resulted in 
complete removal of bound antibodies from surface. Repeated injections of monoclonal 
antibodies or plasma samples over each regenerated surface resulted in reproducible antibody 
binding levels on the surface which indicated that immobilized glycoconjugates were stable.  
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3.1.8 Statistical Analysis 
The significance of the difference between the binding levels on different surfaces were 
evaluated using a two-tailed student’s t-test with p<0.05 indicating a significant difference. The 
difference between binding levels of different plasma samples on different surfaces were 
compared using one-way analysis of variance (ANOVA). 
3.1.9 Measurement of the Kinetics of Antibody-Antigen Interactions 
Monoclonal antibodies were all diluted in the dilution buffer (HBS-EP) to the following final 
concentrations: 0.01, 0.02, 0.04, 0.08, 0.15, 0.30, 0.61 and 1.22 nM for A-16 antibodies; 0.7, 1.4, 
2.9, 5.8, 11.7 and 23.5 nM for Anti-A series1; and 0.1, 1.7, 3.5, 6.9, 13.9, 55.6 and 111.1 nM for 
clone F98 7C6-4 antibodies. The range of antibody concentrations was chosen to cover a 
complete range of binding levels to immobilized Atri-PAA1000-biotin. Antibodies at each 
concentration were injected twice over the control and test surfaces. Injections were performed at 
a flow rate of 75 µl/min for three minutes in a random concentration order. Each injection was 
followed by a 10 minute dissociation time and a single injection of 10 mM glycine-hydrochloric 
acid (Glycine-HCl) (pH 1.5) at a flow rate of 90 µl/min for 30 seconds to remove the bound 
antibodies from the surface. A two minute stabilization time after the regeneration step followed 
each cycle.  In all of the above experiments, a blank injection of the running buffer was included. 
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3.1.10 Kinetic Analysis 
We used the approach given by Fagerstam et al. [111] to obtain kinetic constants for interactions 
between immobilized Atri antigens (Ag) and monoclonal anti-A antibodies (Ab). Assuming a 
simple 1:1 interaction model, the net rate of antibody-antigen complex formation (Ab-Ag) is 
given by : 
 
][]][[/][ AgAbkAgAbkdtAgAbd da −−=−  (3-1) 
  
 
where ak  and dk   represent the association and dissociation rate constants, respectively and t  
represents time. Equation (3-1) can be expressed in terms of the resonance signal, R :   
 
RkRRCkdtdR da −−= )(/ max  (3-2) 
    
 
where R  is the binding level at time t  and is assumed proportional to the amount of Ab-Ag 
complexes formed, C  represents concentration of the antibodies in the solution and 
maxR represents antibody removal capacity of the immobilized antigens in resonance units.  
Equation (3-2) can be rearranged to give: 
 
max/ CRkRkdtdR as +−=  (3-3) 
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where,  
 
das kCkk +=  (3-4) 
  
 
Following equation (3-3), dtdR /  was linearly regressed against R  at various antibody 
concentrations and the slopes of the regression yielded sk  . A linear regression of sk  against C  
then yielded ak  according to equation (3-4). During the dissociation phase, antibody 
concentration is zero and equation (3-2) simplifies to: 
 
RkdtdR d−=/  (3-5) 
  
 
The solution to equation (3-5) is: 
 
tkRR do =)/ln(  (3-6) 
  
 
where oR  represents the response at the beginning of the dissociation phase. Dissociation rate 
constants ( dk ) were calculated by a linear regression of )/ln( RRo  versus t  according to 
equation (3-6). Equilibrium dissociation constants ( DK ) were calculated as the ratio of dk  over 
ak . For each anti-A antibody clone, ak  was reported as the average of two independent 
measurements and dk  was measured as the average of a series of measurements for the range of 
antibody concentrations studied in the experiment.    
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3.2 RESULTS 
3.2.1 Effect of the size of PAA on Antibody removal Capacity of Glycopolymers 
Our goal was to evaluate the effect of molecular weight of polyacrylamide scaffold on the 
antibody removal capacity of Atri-PAA-biotin conjugates. Atri-PAA30-biotin and Atri-PAA1000-
biotin (containing 20 mol% carbohydrate and 5 mol% biotin) were synthesized. Analogous 
glycoconjugates containing B antigens (Btri-PAA30-biotin and Btri-PAA1000-biotin) and the 
polymer without carbohydrate residues (PAA1000-biotin) were used as controls for the SPR 
experiments. All glycoconjugates were immobilized on flow cells of SA sensor chips. 
Immobilization was performed until maximum loading on each surface was reached. The 
maximum loading capacity of surface was estimated 1 ng/mm2 for both 30 and 1000 kDa 
glycoconjugates (Figure 3-1). Since in both 30 and 1000 kDa glycoconjugates  20 mol% of the 
active acrylate groups were replaced with trisaccharide antigens, equal immobilization level (1 
ng/mm2 ) of 30 and 1000 kDa glycoconjugates resulted in equal loading of the chips with blood 
group A or B trisaccharide antigens. Three clones of monoclonal anti-A antibodies and three 
different samples of plasma type B (polyclonal anti-A antibodies) were injected over 
immobilized antigens on control and test surfaces to measure maximum antibody removal 
capacity of each surface. The nonspecific binding level of monoclonal antibodies on the control 
surfaces (Btri-PAA30-biotin and Btri-PAA1000-biotin) was less than 10% of their binding level on 
all test surfaces. To obtain the net binding levels, the nonspecific binding levels on control 
surfaces were subtracted from the binding levels on test surfaces. Figure 3-2 shows the net 
amounts of three clones of monoclonal anti-A antibodies binding to immobilized conjugates 
(Atri-PAA30-biotin or Atri-PAA1000-biotin). Atri-PAA1000-biotin showed greater capacity for 
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monoclonal antibody removal compared to Atri-PAA30-biotin. The percentage of increase in  
capacity was significant (P<0.05), but different between the three clones of antibodies (60% for 
A16, 30% for Anti-A series1 and 15% for F98 7C6-4). 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-1: Immobilization of Atri-PAA30-biotin on streptavidin-coated 
sensor chips. 
 
 
Figure 3-3 shows the removal capacity of different surfaces in interactions with  anti-A 
antibodies present in three plasma samples of type B donors. Anti-A antibody binding levels to 
Atri-PAA1000-biotin increased by 150% for two of the plasma samples (#1 and #3) and by 88% 
for sample (#2) compared to their binding level on Atri-PAA30-biotin. Average nonspecific 
binding levels of plasma antibodies to control surfaces were 50% and 24% of their specific 
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binding to test surfaces containing immobilized Atri-PAA30-biotin and Atri-PAA1000-biotin, 
respectively. Antibodies in all three plasma samples showed equal binding levels to both Btri-
PAA1000-biotin and Btri-PAA30-biotin. Thus, increase in the size of the PAA linker did not 
increase the nonspecific binding on surface. Additionally, there was no difference in the 
nonspecific binding levels to Btri-PAA1000-biotin, Btri-PAA30-biotin or PAA1000-biotin.  
3.2.2 Effect of the Carbohydrate Content on Antibody Removal Capacity of 
Glycopolymers 
We hypothesized that in polyacrylamide glycoconjugates such as Atri-PAA-biotin, the space 
between the carbohydrate residues is not fixed. A randomly coiled flexible polyacrylamide 
backbone could provide multivalent binding with antibodies by adjusting the spacing between 
copies of A- trisaccharides. Based on this hypothesis, an increase in carbohydrate content of 
Atri-PAA1000-biotin from 20 mol % to 50 mol % could affect the antibody removal capacity of 
glycopolymers by changing their flexibility. To check this hypothesis, Atri-PAA1000-biot with 20 
mol % and 50 mol % of blood group A- trisaccharide content were synthesized. We did not 
observe a significant difference in antibody removal capacity of Atri-PAA1000-biot with 20 or 50 
mol % A-trisaccharide content  (Figure 3-4). Any further increase in the A-trisaccharide content 
is unlikely to improve the binding capacity of surface, possibly due to an increase in the steric 
hindrance between the binding antibodies when PAA becomes too closely populated with 
conjugated A-trisaccharides.  
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Figure 3-2: Antibody removal capacity of glycopolymer immobilized surfaces.  Low 
(Atri-PAA30-biot) and high (Atri-PAA1000-biot) molecular weight glycopolymers 
were deposited on streptavidin-coated sensor chips at the loading density of 1 
ng/mm2. Three clones of IgM anti-A antibodies (A16, Immucor and Dominion) were 
injected over glycopolymer immobilized surfaces until equilibrium was reached.  
The nonspecific binding levels on control surfaces were subtracted from the binding 
levels on test surfaces. The amount of bound antibodies per unit surface area was 
measured in resonance units (1000 RU~ 1 ng/mm2). 
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Figure 3-3: Antibody removal capacity of glycopolymer immobilized surfaces 
(Atri-PAA30-biot and Atri-PAA1000-biot) in their interactions with polyclonal anti-A 
antibodies. Analogous glycoconjugates containing B antigens (Btri-PAA30-biotin and 
Btri-PAA1000-biotin) and the polymer without carbohydrate residues (PAA1000-
biotin) were used as controls. Anti-A antibody titer in plasma samples #1, #2 and #3 
were 32, 16 and 16, respectively. 
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Figure 3-4: Effect of the carbohydrate content on antibody removal capacity 
of glycopolymer immobilized surfaces. Atri-PAA1000-biot molecules with 20% or 
50% A-trisaccharide content were deposited on streptavidin-coated sensor chips. 
Three plasma samples and a sample of monoclonal IgM anti-A antibodies 
(Immucor) were injected over glycopolymer immobilized surfaces until equilibrium 
was reached. Anti-A antibody titer in plasma samples #2 and #3 and Immucor 
antibodies were 16 and in plasma sample #1 the antibody titer was 32. 
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3.2.3 Binding Kinetics of Anti-A Antibodies to High Molecular Weight Glycopolymers 
We chose Atri-PAA1000-biot as the candidate synthetic A antigen because it enhanced antibody 
binding capacity of surface by two to three fold compared to the surfaces equally immobilized 
with Atri-PAA30-biot.   We then measured the kinetics of binding between Atri-PAA1000-biot and 
monoclonal anti-A antibodies. Atri-PAA1000-biot and Btri-PAA1000-biot were immobilized on test 
and control flow cells of SA sensor chips at loading levels of 0.046 and 0.056 ng/mm2, 
respectively. Figure 3-5 shows net binding curves during double injections of A-16 antibodies 
(with concentrations ranging between 0.01 and 1.22 nM) over Atri-PAA1000-biot at 25 oC. Net 
binding curves were obtained by subtracting response levels on control flow cells form response 
levels on test flow cells. Our regeneration protocol resulted in complete surface regeneration 
after each cycle. Repeated injection of antibodies at each concentration following surface 
regeneration resulted in reproducible antibody binding levels, indicating that immobilized Atri-
PAA1000-biot were stable on test surfaces throughout the experiment. The net binding curves 
were analyzed in terms of the kinetic model described in section (3.1.10). Initially first order rate 
constants ( sk ) were obtained as the slope of the plots after regression of dtdR /  against R , 
according to equation (3-3), during the association phase (Figure 3-6). Subsequently, association 
rate constants ( ak ) for each set of monoclonal antibody-Atri conjugate interaction were obtained 
from equation (3-4) as the slope of the plots by linear regression of sk  against C  (Figure 3-7). 
There was good agreement between our experimental data during the association phase and the 
fitting curves generated based on the 1:1 interaction model (R2>0.96 for all fits). To obtain 
dissociation rate constants, response levels from the dissociation phase were transformed into a 
plot of )/ln( RRo  versus time, see equation (3-6). Figure 3-8 shows a transformed dissociation 
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phase during 10 minutes dissociation time for A-16 antibodies. The dissociation phase 
demonstrated two stages, with faster antibody release occurring during the initial stage. This data 
deviated from the 1:1 interaction model, most likely due to bivalent or multivalent binding of a 
fraction of the binding IgM antibody population. Due to the comparable sizes of IgM and high 
molecular weight glycoconjugates, multivalent binding interaction between IgM antibodies and  
 
 
 
Figure 3-5: Real time plot of monoclonal anti-A antibody (A16) binding level 
on Atri-PAA1000-biot immobilized surface. 
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Figure 3-6: Plots of  dR/dt  versus R  for three sets of monoclonal anti-A 
antibodies binding to immobilized Atri-PAA1000-biot. a: A-16 (Hematological Center) , 
b: Series1 (Immucor)  c:  F98 7C6-4 (Dominion). 
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  Atri-PAA1000-biot is expected. To minimize these effects in our analysis, we adopted the 
method explained by Morton et al. [123]  and utilized only the initial stage of dissociation data in 
our analysis (Figures 3-8 and 3-9). This method excludes the population of antibodies that show 
smaller dissociation rate constants due to multivalent binding to immobilized A-trisaccharides. 
The initial dissociation time range in each case was arbitrarily chosen from t=0 to the time point 
at which ln (Ro/R) reached 40% of its equilibrium value (Figure 3-8). The coefficient of 
determination (R2) for linear regression of ln (Ro/R) versus time during the initial dissociation 
phase was greater than 0.96 in all cases. Table 3-1 summarizes the association and dissociation 
rate constants obtained for the three clones of anti-A antibodies. 
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Figure 3-7: Plot of the pseudo first order rate constant (ks) versus 
monoclonal antibody concentration (C)  for a: A-16 (Hematolog), b: Series1 
(Immucor), c: F98 7C6-4 (Dominion). 
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Figure 3-8: Plot of ln (Ro/R) versus time demonstrates two stages of dissociation 
phase with faster antibody release occurring during the initial stage. R and Ro 
represent the antibody binding level on surface at any time point (t) and at the 
beginning of the dissociation phase, respectively. The plot shows the dissociation 
phase following injection of A16 monoclonal antibodies, at a concentration of 0.0055 
nM. 
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Figure 3-9: Measurement of dissociation constant for binding interactions 
between  a: A-16 (Hematolog), b: Series1 (Immucor), c: F98 7C6-4 (Dominion). 
antibodies and Atri-PAA1000-biot immobilized surface. The slope of the plot 
corresponds to the dissociation constant, kd. 
kd = 0.0007 s-1
R2 = 0.9881
0
0.04
0.08
0 40 80t (s)
ln
(R
o
/R
)
kd= 0.0012 s-1
R2 = 0.9923
0
0.04
0.08
0.12
0 20 40 60t (s)
ln
(R
o
/R
)
kd=0.0089 s-1
R2 = 0.995
0
0.4
0.8
0 20 40 60t (s)
ln
(R
o
/R
)
A16 (Hematolog)
Series 1 (Immucor)
F98 7C6-4 (Dominion)
a
b
c
 62 
 
Table 3-1: Kinetic and equilibrium affinity constants for binding interactions 
between three clones of IgM anti-A and Atri-PAA1000-biot.  
 
Antibody 
Clone/ Source 
ak  ( M-1s-1) dk (s-1) DK (M) )( D
aCk
Da
i
sa
=  
A-16 
(Hematological 
Center) 
(1.8±0.1) 710×  (3.8±2.2) 410−×  2.1 1110−×  785 
Series1 
(Immucor) 
(1.2±0.2) 610×  (1.4±0.7) 310−×  1.2 910−×  52 
F98 7C6-4 
(Dominion) 
(5.2±1.2) 510×  (6.4±3.7) 310−×  1.2 810−×  23 
 
 
3.3 DISCUSSION 
Polymer beads or hollow fiber membranes on which synthetic antigenic determinants of A and B 
blood groups are immobilized have been previously used for specific removal of anti-A or anti-B 
antibodies [24-25, 32]. Membranes are associated with less pressure drop, faster flow rates, and 
less diffusion limitations than packed beds of porous beads [34] making them the more attractive 
option as support matrices in hemoperfusion systems. However, lower removal capacity due to 
limited surface area for ligand immobilization is a major obstacle in membrane adsorption 
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techniques. Affinity and accessibility of small haptens (such as blood group A and B 
trisaccharides) for target binding molecules (such as anti-A and anti-B antibodies) could be 
greatly enhanced by using a flexible spacer in linking the small molecule to the support matrix. 
Flexible spacers increase lateral mobility of immobilized haptens and facilitate the binding 
interaction. The use of spacers is even more crucial when hollow fibers are used as support 
matrices because of their limited surface area for ligand immobilization. Polymeric spacers such 
as polyethylene glycol (PEG), poly-L-Lysine (PLL) and polyacrylamide (PAA) have been 
previously proposed as linkers to enhance binding affinity and removal capacity of immobilized 
ligands. Synthetic A and B antigens have been used both with relatively short aliphatic chains (6-
17 carbon atoms in length) as in Synsorb® and Glycosorb® columns or  with  longer multivalent 
PAA spacers (30-50 kDa).  Nevertheless, limited antibody binding capacity is still the major 
challenge especially with hollow fiber based antibody removal devices (92).  In this work, we 
conjugated 1000 kDa PAA spacers to synthetic blood group A-trisaccharide antigens and 
compared their anti-A removal capacity with the previously used 30 kDa glycoconjugates [32]. 
The increase in the size of PAA conjugates resulted in two to three fold increase in removal 
capacity per unit surface area. With this estimated increase in capacity, a hollow fiber based 
antibody removal device (such as the SAF device) with a surface area of about 1.5 to 2 m2 would 
provide sufficient capacity for 100% antibody capture from blood in a single device. 
Few studies have been performed to evaluate the effect of the size of PAA on affinity and 
removal capacity.  Shilova et al. [121] observed no difference in the anti-B antibody binding 
levels on to low (30-50 kDa) or high (1000-2000 kDa) molecular weight Btri-PAA 
glycoconjugates physically adsorbed on ELISA plates. However, high molecular weight Btri-
PAA conjugates inhibited type B erythrocyte agglutination at a 100 times lower concentration 
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than low molecular weight Btri-PAA in the solution phase reaction [121]. We hypothesized that 
PAA glycoconjugates immobilized on streptavidin covered surfaces are presented in two ways. 
In one scenario, Atri-PAA-biotin molecules are coupled to surface by all of their biotin residues 
thereby adopting the “stretched” conformation (Figure 3-10-a). This conformation reduces 
mobility of the polymer backbone and interferes with interaction of the glycoconjugates with 
antibodies. In the stretched conformation antibodies will interact equally with Atri-PAA-biotin 
glycopolymers regardless of their molecular weight. In the second situation, Atri-PAA-biotin 
polymers bind to the surface by one or a few biotin molecules, and the glycopolymers keep their 
conformation close to a random coil (Figure 3-10-b). The diameter of Atri-PAA1000-biotin and 
Atri-PAA30-biotin molecules in the random coil conformation is estimated to be 500-600 Å and 
90 Å, respectively [120]. IgM antibodies (about 300-400 Å) are comparable in size to Atri-
PAA1000-biotin and are therefore capable of binding to most of the immobilized glycopolymer 
molecules, whereas the size of IgM antibodies does not allow binding of them to each of 
immobilized Atri-PAA30-biotin molecules (Figure 3-10-b). Our results agreed well with the 
second mechanism, i.e. high molecular weight glycoconjugates provided better accessibility of 
blood group A-trisaccharides for antibody binding. The second mechanism could also explain 
the earlier observed difference between antibody binding levels to glycoconjugates of different 
molecular weights in the solution phase [121]. 
We measured the kinetics of interaction between our candidate glycoconjugates (Atri-
PAA1000-biotin) and anti-A antibodies to show that conjugation of synthetic A-trisaccharides to 
polyacrylamide spacers and immobilization of the conjugates on surfaces did not adversely 
interfere with A-trisaccharide-anti-A antibody binding interactions. Association rate constants 
ranging between 103 and 107 M-1s-1 and dissociation rate constants ranging between 10-6 and 10-2 
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s-1 have been previously reported for interactions between various pairs of monoclonal antibodies 
and their specific antigens [124], [125], [126], [127], [112, 128]. The kinetic and affinity 
constants calculated in this study fall within the range of antibody-antigen interaction kinetic 
constants, with a trend towards higher affinity interactions. 
 
 
 
 
 
 
 
 
 
 
Figure 3-10: Two hypothetical presentations of immobilized glycopolymers 
on surface. a: Atri-PAA-biotin polymers are coupled to surface by all of their biotin 
residues thereby adopting the “stretched” conformation. b: Atri-PAA-biotin 
polymers bind to the surface by one or a few biotin molecules, and the 
glycopolymers keep their conformation close to random coil. 
 
 
 
 
a b
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Two different levels of antigen loading on SA sensor chips were used in our studies. For 
our kinetic analysis, we attempted to immobilize the minimum amount of Atri-PAA1000-biot 
(0.046  ng/mm2) on SA sensor chips to minimize the effect of mass transfer on the kinetic 
analysis [122],[129],[130],[131]. The low loading level of antigens also minimizes crowding of 
antigens on the surface and as a result, multivalent interactions between binding IgM antibodies 
and immobilized antigens are minimized. This behavior was ideal for quantification of the 
kinetics of interaction between single antibody binding sites (Fab) and immobilized Atri-
PAA1000-biot. However, to mimic the real application in SAF when measuring the binding 
capacity of surface, antigens needed to be immobilized on the surface at their maximum loading 
capacity (1 ng/mm2). This ensured that the steric effects in interactions between immobilized 
glycoconjugates and antibodies were similar in our experimental set up and in the real 
application.  
We previously developed a mathematical model capable of predicting the dependence of 
antibody removal rate on key design parameters in our proposed SAF devices [33],[32]. This 
mathematical model established that maximum antibody removal rate could only be achieved in 
SAF devices under a diffusion limited antibody transport regime. In other words, optimum 
capture rate occurs only when antibody removal becomes independent of antibody-antigen 
reaction rates. The dimensionless Damkohler number (Da) defined as ( )
D
aCk
Da
i
sa
=  was used to 
determine the conditions needed for antibody transport to occur in a diffusion-limited regime. 
Based on this model a Da number of 10 or greater was required to achieve maximum antibody 
removal rate in the proposed SAF design. Both the surface binding capacity ( isC ) and the 
intrinsic association rate constant ( ak ) for antibody-antigen interaction are required for 
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calculation of Da and an assessment of our design of antibody filters. The intrinsic association 
constants ( ak ) were directly measured for three sets of monoclonal anti-A antibodies and were 
found to be 18, 1.2 and 0.52 cm3/nmol.s for clones A16, series 1 and F98 7C6-4. The magnitude 
of Da was then calculated for each set of monoclonal antibodies binding to Atri-PAA1000-biot 
assuming a surface capacity ( isC ) of 0.0017 nmol/cm2 (twice the surface capacity measured 
previously for Atri-PAA30-biot by Gautam et al. [32]). The antibody diffusivity coefficient ( D ) 
was assumed to be 3.9×10-7 cm2/s and the fiber inner radius ( )a  was 0.01 cm. The value of Da  
for each monoclonal antibody is listed in Table 3-1.  Values of Da  for all three antibody clones 
were greater than 10, supporting the hypothesis that antibody removal rate becomes diffusion 
limited and independent of the specific affinity for antibody-antigen interaction in an Atri-
PAA1000-biotin-immobilized hollow fiber based antibody removal device.  
Further experimental work is required to establish the bioactivity and biocompatibility of Atri-
PAA1000-biotin in antibody capture from whole blood in the SAF device. Rieben et al. previously 
characterized the biocompatibility of Atri-PAA30 immobilized on porous particles in their 
interaction with plasma antibodies [24]. Hout et al. described the feasibility of antibody capture 
from whole blood in an earlier-generation SAF device with Neutr-AB®, an animal based A and B  
glycoprotein antigen, immobilized on inner lumens of the hollow fibers [31]. We propose that 
the custom-made high molecular weight glycopolymer we have presented is a promising 
synthetic A antigen for construction of anti-A immunoadsorption devices. A SAF device which 
incorporates these high molecular weight glycoconjugates as synthetic A antigens may aid in 
meeting the target anti-A antibody titer reduction of three to four titer steps. 
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4.0  DEVELOPMENT OF A SIMPLE MATHEMATICAL MODEL OF ANTI-A/B 
ANTIBODY CAPTURE IN INTEGRATED BEAD AND FIBER ANTIBODY FILTERS 
In Chapter 2.0, we discussed development of our previous prototype antibody filtering devices 
(SAF), in which synthetic A-trisaccharide (Atri) antigens conjugated to low molecular weight 
(30-50 kDa) poly-N hydroxyethylacrylamide (PAA) spacers were immobilized on the luminal 
surfaces of dialyzer fibers potted into modules [32]. As we also discussed in Chapter 2.0, initial 
evaluation of anti-A antibody removal capacity and capture rate in appropriately scaled down 
SAF devices indicated that a 5 to 6-fold increase in removal capacity per unit surface area of the 
modules was required to achieve 100% antibody removal in a clinically relevant time scale [32]. 
In Chapter 3.0, we showed that by using high molecular weight (1000-2000 kDa) 
polyacrylamide glycoconjugates as the immunoadsorbent material in SAF devices, antibody 
removal capacity per unit surface area could be increased by 2-3 fold. We concluded that by 
immobilizing high molecular weight glycoconjugates on the luminal surface of SAF fibers, we 
would achieve a target anti-A antibody titer reduction of three to four titer steps in each device. 
However, so far we have faced a number of difficulties in obtaining consistent immobilized 
antigen densities in SAF devices during immobilization of high molecular weight 
polyacrylamide glycoconjugates. While parallel efforts were ongoing in our team to improve 
antigen immobilization chemistry and further increase antibody removal capacity of SAF 
devices, we started developing a new antibody removal device, based on integrated 
 69 
microfiltration fibers with antibody capturing beads uniformly distributed within the interstitial 
fiber space (BSAF device). Antibody removal in BSAF devices occurs by Starling recirculation 
flow of plasma between the fiber and bead-containing shell compartment in combination with 
antibody diffusing and binding within the shell-side porous beads. Similar to our SAF devices, 
the BSAF modules are compatible with whole blood perfusion and remove blood group 
antibodies in a one step process that does not require a separate plasmapheresis unit. 
Additionally, due to the vast surface area of the beads for antigen immobilization, antibody 
removal capacity of the BSAF modules is practically infinite, in relation to the range of anti-A/B 
antibody concentrations naturally found in blood.  
In this chapter, we will describe development of a simple mathematical model to guide 
the choice of key design and operational parameters for a clinical BSAF device. The model 
demonstrates that for a given flow rate and reservoir volume, antibody removal rate in a BSAF 
depends on the magnitude of a lumped dimensionless parameter, BLmk / sQ . This term 
characterizes the ratio of antibody uptake rate by the beads to the Starling flow rate in the device. 
Three distinct antibody removal regimes were observed with the following approximate 
boundaries: diffusion limited ( 1/ ≤sBL Qmk ), intermediate ( 10/1 << sBL Qmk ) and perfusion 
limited ( 10/ ≥sBL Qmk ). For a given BSAF geometry, fiber hydraulic permeability, reservoir 
volume and flow rate, the highest antibody removal rate is predicted for the perfusion limited 
regime, when 10/ →sBL Qmk . The model also shows that once perfusion limited antibody 
removal rate in a BSAF device is obtained, further increase in antibody removal rate is possible,  
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solely by increasing the flow rate in the device. We validated the key predictions of the model in 
a series of in vitro monoclonal anti-A antibody capture studies in BSAF devices, packed with 
anti-A specific beads. Once validated, the model was used to conceptually design a BSAF device 
that would generate a clinically relevant rate of anti-A removal.  
4.1 MODEL ANALYSIS 
4.1.1 Model geometry 
The BSAF system is modeled as a bundle of N  identical cylindrical microfiltration hollow 
fibers of inner diameter, id  , and length L . The fibers are equally spaced and fixed in a 
cylindrical housing of length L . A slurry of beads in buffer solution is recirculated through the 
interstitial space between the fibers. The bead recirculation loop serves solely to maintain a well-
mixed and uniformly distributed bead slurry within the fiber interstitial space. 
4.1.2 Quantification of Starling Flow 
Starling flow is the flow of fluid out of the fiber into the shell side that returns back into the 
fibers [132-133]. Starling flow occurs due to a transmural pressure gradient between the two 
compartments. Assuming a constant pressure, sP , in the shell side, a mass balance on a 
differential element z∆  of any single fiber yields the governing mass transfer equation:   
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(4-1) 
 
where )(zq  is the steady state flow rate inside a single fiber as a function of the axial position z , 
K  is the hydraulic permeability of each fiber and )(zP  is the pressure in the fiber. The axial 
pressure gradient inside each hollow fiber is obtained assuming a fully developed laminar 
viscous flow [134]: 
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where, µ  is the viscosity of the fluid.  
Combining equations (4-1) and (4-2), a governing differential equation for the flow 
through a fiber is obtained:  
 
 0)(22
2
=− zq
dz
qd β  (4-3) 
 
where,   128 3
2
id
Kµβ = . There is no net ultrafiltration flow in the BSAF. Therefore, the boundary 
conditions for equation (4-3) are: NQLzqzq /)()0( ==== , where Q  is the flow rate in the 
device.  The analytical solution to equation (4-3) with associated boundary conditions is: 
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The Starling flow, sQ , is the integrated total flow out of the fibers to the shell side and is 
given by: 
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4.1.3 Quantification of Antibody Capture Rate in BSAF 
The shell compartment of the BSAF is modeled as a well-mixed slurry of beads. The inlet stream 
to the shell compartment is the Starling flow through the first half of the fibers, which has an 
antibody concentration, )(tC , equal to the concentration of antibodies in the inlet stream of the 
BSAF. The outlet stream from the shell compartment is the Starling flow back into the second 
half of the fibers with an antibody concentration, )(tCs , which is obtained from an antibody 
mass balance in the shell compartment. 
Assuming that BSAF devices have an infinite antibody adsorption capacity in relation to 
the maximum amount of antibodies in the reservoir (see section 4.3.1 for justification), the rate 
of antibody adsorption per unit mass of the beads is obtained from the following first order 
relation: 
 
)(tCk
dt
dR
sL=  
(4-6) 
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where, )(tR  is the amount of antibody adsorbed per unit mass of the beads as a function of time 
and Lk  is a first order rate constant that accounts for antibody diffusion and adsorption into the 
beads.  
Assuming a quasi steady state adsorption in the shell compartment, the governing 
equation for capture of antibodies in the shell is obtained from:  
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where Bm  is the mass of beads. This yields the following equation for )(tCs : 
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Our interest is to obtain an equation for the antibody concentration in the reservoir, )(tC . 
A mass balance for antibody in the fiber side yields: )]()([ tCtCQ
dt
dCV ssR −= , where RV  is the 
volume of the reservoir. Using equation (4-8), the antibody mass balance is : 
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Assuming an initial reservoir antibody concentration, iC , this leads to the following 
analytical solution for )(tC : 
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4.2 MATERIALS AND METHODS 
4.2.1 Preparation of Affinity Beads 
All chemicals were obtained from Fisher Scientific (Pittsburgh, PA) unless specified. Specific 
determinant fragments of blood group A-trisaccharide antigen (Atri), 
GalNAcα1−3[Fucα1−2]Galβ−, and B-trisaccharide antigen (Btri),  Galα1−3[Fucα1−2]Galβ−, 
conjugated to activated poly(4-nitrophenyl acrylate) of molecular weight 30 kDa (pNPA30) were 
synthesized at Shemyakin and Ovchinnikov Institute of Bioorganic Chemistry (Russian 
Academy of Sciences, Moscow, Russia) as described previously [119], [120]. The synthesized 
polyacrylamide glycoconjugates contained 20 mol% of the A or B trisaccharides  (Atri-pNPA30 
or Btri-pNPA30). 
Cyanogen bromide (CNBr) activated, cross linked Sepharose® CL-4B beads (Sigma-
Aldrich, St. Louis, MO) were initially left to swell in cold (4oC) 1mM hydrochloric acid (HCl) 
for 30 minutes. The gel was then rinsed and transferred to an equal volume of 0.1 M sodium 
carbonate buffer (pH 9.6) containing 1M ethylenediamine. The reaction mixture was left at 22oC 
for 24 hours.  The gel was then rinsed and suspended in an equal volume of 10% dimethyl 
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sulfoxide (DMSO) in 0.1 M sodium carbonate buffer (pH 9.6) containing 0.15 mg/ml of Atri-
pNPA30 or Btri-pNPA30 . The reaction mixture was left at 22oC for another 24 hours. Finally, to 
block the unreacted active acrylate sites, the gel was left in an equal volume of 10% DMSO in 
0.1 M sodium carbonate buffer (pH 9.6) containing 10% 2-aminoethanol at 22oC for 24 hours. 
The gel was then rinsed and suspended in an equal volume of cold (4 oC) 1.1 M sodium 
bicarbonate solution containing 5% acetic anhydride for 30 minutes to deactivate any remaining 
free amine groups. The resin was thoroughly rinsed with water and stored in phosphate buffered 
saline (PBS) (pH 7.4) at 2-8 oC. 
Cross linked Sepharose® CL-6B beads (Sigma-Aldrich, Louis, MO) were not available 
in already activated form and were activated using a  standard CNBr activation chemistry [135]. 
Briefly, the gel was suspended in an equal volume of distilled water. CNBr (Sigma-Aldrich, St. 
Louis, MO) was added to the gel suspension (0.2 g/ml) and the pH of the reaction mixture was 
kept at 11.0 by dropwise addition of 10N sodium hydroxide (NaOH) while maintaining the 
temperature of the reaction at 23-25 oC. This reaction proceeded for approximately 15 minutes 
until the pH stabilized. The gel was quickly washed with ice cold water and ice cold 0.1M 
sodium bicarbonate buffer (pH 9.6). The gel was then aminated and modified using the same 
protocol as described above for the CL-4B beads. 
4.2.2 Determining Adsorption Capacity and Antibody Uptake Kinetics within Modified 
Beads  
One ml polypropylene Rezorian cartridges (Supelco, St Louis, Mo) equipped with luer plugs, 
caps and polyethylene frits were packed with 0.2 g of CL-4B or CL-6B beads on which synthetic 
A or B antigens were immobilized, as previously described. The packed columns were initially 
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primed with 5 ml of PBS buffer containing 0.05% Tween (PBS/0.05% Tween). Antibody 
solution was prepared by diluting murine monoclonal anti-A IgM antibodies (Anti-A series1, 
Immucor Inc., Norcross, GA, USA) in PBS/0.05% Tween to the final concentration of 15 µg/ml. 
Various volumes (3 to 20 ml) of the antibody solution were then recirculated through the 
columns at two different flow rates, 0.5 and 1.5 ml/min, for 90 minutes to ensure that antibody 
uptake kinetics were not dependent on flow rate. Small samples (10 µl) were taken from the 
reservoir at time points: 0, 5, 10, 15, 30, 60 and 90 minutes. The concentration of antibodies in 
the reservoir were determined by enzyme-linked immunosorbent assay (ELISA) as described 
previously [116]  Antibody removal capacity of the beads was calculated from the difference 
between the antibody concentrations of reservoir in the beginning and in the end of capture 
experiment for those columns in which the beads reached their saturation limit. 
The first order rate constant, Lk , was determined by analyzing antibody removal by 
packed bead columns, through which 3 ml of antibody solution was recirculated at two flow rates 
of 0.5 and 1.5 ml/min. Assuming that the local rate of antibody removal in the packed bead 
column is governed by equation (4-6), the governing differential equation for the axial variation 
of antibody concentration in the packed bead  column is: 
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where )(zCc  is the pseudo steady state concentration of antibodies in the liquid phase as a 
function of the axial position z  within the column, cL  is the length of the column and cQ  is the  
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flow rate within the column. Integrating equation (4-11) over the length cL  of the column, the 
antibody concentration in the outlet stream is: 
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where )(tC  is the concentration of antibodies in the reservoir as a function of time. Combining 
equation (4-12) with an antibody mass balance in the reservoir:  )]()([ tCtCQ
dt
dCV cLcR −= ,  and 
integrating with respect to time  yields:   
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The reservoir antibody concentration, )(tC , measured at time points: 0, 5, 10 and 15 
minutes was fit to equation (4-13) using the “nlinfit” function in Matlab (Matlab 7.0, The 
MathWorks, Inc., Natick, MA)  to determine the first order rate adsorption constant, Lk .  
4.2.3 Fabrication of the BSAF Modules  
A polycarbonate tube (K-mac Plastics, Wyoming, MI) of 25 cm length, 0.635 cm inner diameter 
and 1.27 cm outer diameter was used as the shell case of our BSAF module. Two circular holes 
(0.5 mm) were placed in the outer surface of the case at 1 cm from each end of the module and 
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two polycarbonate female luer fittings (Value Plastics, Fort Collins, CO) were glued to each hole 
using UV light curing (DYMAX, Torrington, CT). Twenty polyethersulfone microfiltration 
hollow fiber membranes (MicroPES®, Membrana GmbH, Wuppertal, Germany) of 0.03 cm 
inner diameter and 0.01 cm wall thickness were aligned and placed in the center of the 
polycarbonate housing in a manner to leave approximately 3 cm protruding from each end of the 
housing.  The ends were filled with hot glue, and the excess glue was tomed with a razor blade 
once hardened. Polycarbonate caps with luer fittings were fabricated and attached to both ends of 
the devices using UV light curing adhesive.  
4.2.4 Measurement of Hydraulic Permeability of Fibers 
Figure 4-1-a shows a schematic of the experimental set up for measurement of hydraulic 
permeability of fibers. Distilled water was pumped into the modules with the outlet of the device 
sealed to force ultrafiltration flow into the shell side. Inlet pressure in the fiber compartment, oP , 
and the pressure in the shell compartment, sP , were measured at various flow rates, Q . Using the 
appropriate boundary conditions for the described experimental set up: 
0)(,/)0( ==== LzqNQzq  , the Q versus so PP −  is derived from equation (4-1):   
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where  128 3
2
id
Kµβ = . Assuming Hg.min-mm 1025.1 7−×=µ , hydraulic permeability, ,K was 
calculated from the inverse  slope of the plot of so PP −  versus Q  using an Excel solver tool 
(Microsoft® Office Excel 2003, Redmond, WA).  
4.2.5 Model Validation Experiments 
The model was validated by performing three different types of experiments. First, we compared 
antibody capture rates in BSAF devices loaded with equal mass (1.5 g) of either CL-4B or CL-
6B beads to test whether the model could predict changes in antibody removal rate due to 
changes in the first order rate constant of the beads, Lk . The second set of experiments explored 
the effect of change in mass of beads of a given Lk  on antibody adsorption rate by comparing 
antibody removal rates in BSAF devices loaded with either 1.5 g or 3 g of the same  
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Figure 4-1: Experimental set up for: a: measurement of hydraulic permeability of fibers. b: 
loading a BSAF device with modified beads. 
 
type of beads.  For all experiments, the adsorption capacity of the BSAF devices was at least 
three times greater than the maximum amount of antibodies in the reservoir. In the last set of 
experiments, the reservoir volume was increased from 12 ml to 35 ml while the flow rate was 
maintained at 2.2 ml/min. This was to test whether the model was able to predict the decrease in 
antibody removal rate associated with an increase in the reservoir volume. All experimental 
parameters were set at the baseline values summarized in Table 4-1, unless otherwise specified.  
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Table 4-1: Description of the parameters of the mathematical model and the 
respective values in the model validation experiments. 
 
Parameter 
name 
Description Baseline 
value 
iD  Inner shell diameter (cm) 0.635 
id  Fiber inner diameter (cm) 0.03 
L  Module length (cm) 25 
Bm  Mass of beads (g) 3 
N  Number of fibers 20 
K  Fiber hydraulic permeability ( cm/mm-Hg.min) 0.056 
Lk  First order rate constant (ml/g.min) 3.27 (CL-6B) 1.03 (CL-4B) 
µ  Viscosity ( mm-Hg.min) 
 1025.1 7−×  
iC  
Initial concentration of antibodies in reservoir 
(µg/ml) 10 
Q  Volumetric flow rate (ml/min) 2.2 
RV  Reservoir volume (ml) 12 or 35 
 
The shell side of a BSAF device was packed with modified beads as follows (Figure 4-1-
b): a 50% bead slurry in PBS (pH 7.4) was placed in a beaker, which was connected to one of the 
luer fittings of the shell using a piece of Tygon® tubing (Cole-Parmer, Vernon Hills, IL) via a 
Masterflex peristaltic pump (Cole-Parmer, Vernon hills, IL).  A 1 ml polypropylene Rezorian 
cartridge equipped with polyethylene frit which acted as a filter was connected to the other luer 
fitting in the shell compartment. The bead slurry was then pumped into the shell side at a flow 
rate of 6 ml/min while filtering out the extra liquid through the adjacent shell port and the fiber 
outlet ports. In the end we connected the two shell ports with a piece of Tygon® tubing, primed 
with PBS buffer. Subsequently, the tubing was connected to a Masterflex peristaltic pump and 
the flow rate was set at 6 ml/min. 
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Figure 4-2 shows a schematic of a typical recirculation loop used for antibody removal in 
a BSAF device and Figure 4-3 shows an actual experimental set up of in-vitro antibody capture 
in a BSAF device. The reservoir solution was prepared by diluting monoclonal IgM anti-A 
antibodies (Anti-A series1, Immucor Inc., Norcross, GA, USA) to 10 µg/ml in PBS with 0.05% 
Tween and 5% bovine serum albumin (BSA) (Sigma-Aldrich, St. Louis, MO). The inlet and 
outlet of the fiber side of the BSAF module were connected to the reservoir using Tygon® 
tubing. The antibody solution was recirculated through the module at a flow rate of 2.2 ml/min 
by a Masterflex pump attached to the inlet tubing. Samples were taken from the reservoir at time 
points: 0, 5, 10, 15, 30, 60, 90 and 120 minutes and assayed for the concentration of the 
antibodies using ELISA. 
4.2.6 Data Analysis 
The model predictions of antibody capture in the BSAF given by equation (4-10) were generated 
based on the baseline parameter values summarized in Table 4-1 and a theoretical 
)1(
BLs
s
s
mkQ
QQ
+
−=θ  parameter was calculated for each experiment. To validate the 
mathematical model we fit the experimental capture data to equation (4-10), using the “nlinfit” 
function in Matlab (Matlab 7.0, The Mathworks, Inc, Natick, MA), to determine an experimental 
θ
 
parameter
 
for each experiment
. 
 The model predictions were compared to the experimental 
results by computing the percentage of the relative difference between the experimental and 
theoretical θ  values in each experiment as the following: % relative 
difference= 100exp ×
−
ltheoretica
ltheoreticaerimental
θ
θθ
. Similarly, we calculated the % relative difference 
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between the experimental and theoretical 2/1t  values,  where 2/1t  is  the time point at which 50% 
of the initial reservoir antibody concentration is removed by the BSAF  and is calculated from: 
θ
)5.0ln(
2/1
RVt −= .  
4.3 RESULTS 
4.3.1 Measurement of Model Parameters and Adsorption Capacity of Modified Beads 
Experiments were performed to determine two parameters of our mathematical model: the 
hydraulic permeability of fibers and the first order rate constant of the modified beads. Another 
series of experiments were performed to determine the adsorption capacity per unit mass of the 
modified beads. This data enabled us to calculate the minimum mass of beads required in the 
BSAF devices to maintain an excess of anti-A antibody binding sites in relation to the maximum 
amount of antibodies in the reservoir (hence we justified our assumption of a first order antibody 
removal rate by the beads in BSAF devices, see section 4.1.3). Hydraulic permeability of fibers 
was calculated in each of the fabricated BSAF modules from the inverse slope of the plot of inlet 
transmembrane pressure ( so PP − ) versus flow rate (Q), see equation (4-14). Figure 4-4 shows a 
typical plot of transmembrane pressure versus flow rate. Across the eighteen devices that we 
fabricated and tested for our studies, the average hydraulic permeability was 0.056±0.004 
cm/mm-Hg.min. 
First order rate constant, Lk , of the modified beads was calculated from analyzing 
antibody removal by packed bead columns at recirculation flow rates of 0.5 and 1.5 ml/min. In 
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each case, Lk was calculated from fitting the reservoir antibody concentrations at various times to 
equation (4-13). The results of the fits of equation (4-13) to experimental antibody removal rate 
data and the best-fit values of Lk , along with 2R  values, for each set of modified beads (CL-4B 
and CL-6B) are shown in Figure 4-5. As the recirculation flow rate was increased from 0.5 to 
1.5 ml/min, Lk  increased by 4 % (from 0.92 to 1.03 ml/g.min) for CL-4B beads and by 24 % 
(from 2.48 to 3.27 ml/g.min) for CL-6B beads. The values of Lk , calculated at the flow rate of 
1.5 ml/min, were used in our antibody capture rate model.  
The modified bead adsorption capacities were also calculated from analyzing antibody 
removal by packed bead columns in the recirculation mode. Various volumes (3 to 20 ml) of 
antibody solution were recirculated through columns for 90 minutes. Adsorption capacity of 
modified beads, in the columns that became saturated with bound antibodies, was calculated 
from the difference between initial and final reservoir antibody concentrations (Figure 4-6). The 
antibody adsorption capacity of CL-4B and CL-6B beads was each estimated 153 and 788 µg/g. 
Nonspecific adsorption of anti-A antibodies by control beads, modified with B antigens, was not 
significant. 
4.3.2 Model Predictions 
For a given reservoir volume and Starling flow rate, antibody removal rate in a BSAF 
nonlinearly increases by increasing a dimensionless lumped parameter:  BLmk / sQ . A maximum 
limit of antibody capture rate is achieved when sBL Qmk /  approaches infinity (Figure 4-7). 
Three distinct antibody removal regimes with the following approximate boundaries are shown 
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in Figure 4-7: diffusion limited ( 1/ ≤sBL Qmk ), intermediate ( 10/1 << sBL Qmk ) and perfusion 
limited ( 10/ ≥sBL Qmk ). In a diffusion limited regime ( 1/ ≤sBL Qmk ) antibody removal rate  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-2: Schematic of the BSAF device and a typical set up of the recirculation loop for 
antibody capture. 
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primarily depends on antibody diffusion to the binding sites within the porous beads. Hence, 
antibody removal rate in the diffusion limited regime increases substantially as sBL Qmk /  
increases, but changes insignificantly in relation to an increase in Starling flow rate relative to 
the reservoir volume ( Rs VQ / ). Antibody removal is perfusion limited  when 10/ ≥sBL Qmk . 
In a perfusion limited regime antibody removal rate is solely dependent on the magnitude 
of Starling flow rate relative to the reservoir volume ( Rs VQ / ). No significant increase in the 
antibody removal rate is expected by further increasing the magnitude of sBL Qmk /  in a perfusion 
limited regime. An intermediate regime ( 10/1 << sBL Qmk ) is distinguished in which antibody  
 
 
 
 
 
 
 
 
 
Figure 4-3: An actual experimental set up of in-vitro antibody capture in 
BSAF devices in model validation experiments. 
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removal rate is affected by a combination of antibody diffusion and Starling flow rate in the 
device. For any given value of sBL Qmk /  and reservoir volume, a greater rate of antibody 
removal rate is obtained for a higher value of Starling flow rate (Figure 4-8). 
Figure 4-9 shows that for a given flow rate, reservoir volume, mass of beads and first 
order rate constant, antibody removal rate in a BSAF device increases by increasing the module 
length. 
 
 
 
 
 
 
 
 
 
Figure 4-4: A typical plot of transmembrane pressure (Po-Ps)  versus flow rate ( Q) 
from which fiber hydraulic permeability   is calculated. 
 
4.3.3 Validation of the BSAF Antibody Capture Rate Model  
To validate the model, we first tested its ability to predict changes in antibody removal rates 
associated with changes in sBL Qmk /  for a given BSAF geometry, flow rate and reservoir  
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Figure 4-5: Measurement of first order rate constant, kL , of  modified CL-4B and 
CL-6B beads at two recirculation flow rates (Qc) of 0.5 and 1.5 ml/min. 
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volume. Next, sBL Qmk /  was kept at a constant value and the reservoir volume was increased to 
test the ability of our model to predict the decrease in removal rate associated with a decrease in 
the magnitude of starling flow rate relative to the reservoir volume ( Rs VQ / ), see equation (4-10). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-6: Measurement of antibody removal capacity of CL-4B and CL-6B beads, 
modified with A antigens. Control columns were loaded with CL-4B beads modified 
with B antigens. Antibody removal capacity per unit weight of beads is denoted by 
Rmax . 
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The specific parameters that we varied in the model validation experiments and the 
corresponding values in each experiment are summarized in Table 4-2. The theoretical versus 
experimental values of θ and t1/2  in our model validation experiments are summarized in Table 
4-3. Each experiment is represented by the an identical Experiment number in both Tables 4-2 
and 4-3 . 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-7: Effect of increasing kLmB/Qs on clearance for a given Starling flow rate 
(Qs) of 250 ml/min and a reservoir volume VR of 5000 ml. 
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Figure 4-10 compares antibody removal rates in two sets of BSAF devices packed with 
equal masses (1.5 g) of either CL-4B or CL-6B beads (different Lk values). Flow rate and 
reservoir volume were the same in both cases (2.2 ml/min and 12 ml). Antibody removal rate  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-8: Effect of increasing Starling flow rate (Qs) on clearance, for a given 
value of (kLmB/Qs) and reservoir volume (VR). 
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was predicted in the diffusion limited region for modules packed with CL-4B beads 
( )9.0/ =sBL Qmk  and in the intermediate regime for those modules packed with CL-6B beads 
( )8.2/ =sBL Qmk . Experimental data in both cases showed faster antibody removal  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-9: Effect of increasing module length (L) on clearance, for given values of 
reservoir volume (VR), blood flow rate (Q), mass of beads (mB) and first order rate 
constant of modified beads (kL). 
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than the corresponding model predictions (the experimental t1/2 values were  30% and 38% lower 
than the respective theoretical values in the modules packed with CL-4B and CL-6B beads, 
respectively).  
 
Table 4-2: Description of the baseline values of various experimental parameters in the 
model validation experiments. 
 
 
Experiment 
number 
Bead type kL (ml/g.min) mB (g) VR (ml) 
 
1 
CL-4B 1.03 1.5 12 
 
2 
CL-4B 1.03 3.0 12 
 
3 
CL-6B 3.27 1.5 12 
 
4 
CL-6B 3.27 3.0 12 
 
5 
CL-6B 3.27 3.0 35 
 
 
 
 94 
Table 4-3: Theoretical and experimental values of θ and t1/2 in the model validation 
experiments. 
 
Experiment 
number 
θ 
Theoretical 
(ml/min) 
θ 
Experimental 
(ml/min) 
t1/2  
Theoretical 
(min) 
t1/2 
 Experimental 
(min) 
1 0.82 
 
1.17 
 
 
10.11 
 
7.12 
2 
 
1.12 
 
 
0.68 
 
 
7.42 
 
 
12.22 
 
3 
 
1.30 
 
 
2.11 
 
 
6.42 
 
 
3.95 
 
4 
 
1.49 
 
 
1.42 
 
 
5.57 
 
 
5.84 
 
5 
 
1.49 
 
 
2.39 
 
 
16.26 
 
 
10.15 
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Figure 4-10: Effect of increasing kLmB/Qs on clearance. Two sets of BSAF devices 
were packed with equal mass (1.5 g) of CL-4B or CL-6B beads. Flow rate and 
reservoir volume were  2.2 ml/min and 12 ml, respectively. 
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Figures 4-11 and 4-12 compare antibody removal rates in BSAF devices packed with 1.5 
g and 3 g of CL-4B and Cl-6B beads, respectively (constant Lk values in each case). Increasing 
the mass of beads from 1.5 g to 3.0 g resulted in 42% (CL-4B beads) and 32% (CL-6B beads) 
increase in the observed experimental t1/2 values, whereas based on the mathematical model, we 
were expecting to observe 36% (CL-4B beads) and 15% (CL-6B beads)  decrease in the t1/2 
values under the given experimental conditions. 
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Figure 4-11:   Effect of increasing mass of beads of a given kL on clearance. Two sets of 
BSAF devices were packed with 1.5 g or 3.0 g of CL-4B beads. Flow rate and reservoir 
volume were  2.2 ml/min and 12 ml, respectively. 
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Figure 4-12: Effect of increasing mass of beads of a given kL on clearance. Two sets of 
BSAF devices were packed with 1.5 g or 3.0 g of CL-6B beads. Flow rate and reservoir 
volume were  2.2 ml/min and 12 ml, respectively. 
 98 
Figures 4-13 shows the change in rate of adsorption due to changes in the magnitude of 
Rs VQ / . Both series of BSAF devices were packed with 3 g of CL-6B beads and the flow rate 
was maintained at 2.2 ml/min ( 6.5/ =sBL Qmk  in both cases). The reservoir volume was 
increased from 12 ml to 35 ml. The model predicted 65% increase in t1/2 , whereas the 
experimental results showed 42% increase in this case. 
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Figure 4-13: The effect of adsorption rate changes due to changes in the magnitude of  
Qs/VR. Two sets of BSAF devices were packed with 3.0 g of CL-6B beads. Flow rate was 2.2 
ml/min. The reservoir volume was increased from 12 ml to 35 ml. 
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4.4 DISCUSSION 
An ideal antibody filtering device selectively removes up to 100% of the target antibodies in a 2-
4 hour time period and is biocompatible and simple to operate. To meet these design goals, we 
developed a new antibody filtration device containing microfiltration fibers with antibody 
capturing beads integrated within the interstitial fiber space (BSAF device). Our primary goal in 
this study was to identify the mechanisms underlying antibody capture in these novel BSAF 
devices. To do this we developed a simple mathematical model that predicts antibody removal 
rate in the BSAF as a function of key design and operational parameters, including the first order 
rate constant of antibody capturing beads, mass of the beads, Starling flow rate and the reservoir 
volume. The model was validated by measuring the time course of monoclonal anti-A antibody 
removal in BSAF devices packed with anti-A specific beads. Although we did not observe a 
perfect fit between experimental data and the respective model predictions in this study, we were 
able to show a reasonably good approximation of antibody removal data by the model in all 
cases.  
In-vitro testing of monoclonal anti-A antibody removal in scaled-down prototypes of the 
clinical BSAF (as described in Table 4-4) resulted in 100% antibody removal within two hours 
(Figure 4-13). Gautam et al. previously showed that in-vitro capture of monoclonal anti-A 
antibody in scaled down SAF devices resulted in up to 35% reduction in the anti-A antibody 
concentration [136]. Thus, a significant improvement in anti-A antibody removal was achieved 
in our new BSAF modules. Both SAF and BSAF are immunoadsorbent devices which use low 
molecular weight (30 kDa) A-trisaccharide-polyacrylamide glycoconjugates for anti-A antibody 
adsorption. However, the vast bead surface area for antigen immobilization in BSAF devices 
represents a major advantage in BSAF modules. 
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BSAF devices are similar in principal to the microspheres-based detoxification system 
(MDS), being developed for blood detoxification in liver failure and sepsis [101-104]. The key 
difference between the two systems is the way in which the adsorbents are incorporated within 
the capture loop. The MDS combines the dialysate side of a standard plasma filter with a 
secondary extracorporeal flow loop in which adsorbent particles are suspended. The volume of 
this secondary loop is approximately 300 ml per 1 L of processed blood [104]. Conversely, 
BSAF modules have a shell side whose volume has been specifically calibrated to a size capable 
of housing both the fibers and the bead slurry within a single device.  The module dimensions are 
approximately the same as in a standard plasma filter but contain fewer fibers and therefore 
allow more free shell volume to contain the bead slurry within the fiber interstitial space. 
Although the bead recirculation loop used in this study, seemingly appears similar to that used in 
microspheres-based detoxification system (MDS), fundamentally it only serves the purpose of 
keeping the beads in a continuously mixed and uniformly distributed state.  
We used the model as a guide to design a BSAF device that would generate a clinically 
relevant rate of anti-A removal. Based on the model, the highest antibody removal rate for a 
given Starling flow rate and reservoir volume was predicted for the perfusion limited regime, 
when 10/ →sBL Qmk . Therefore, a first rational step in optimization of design of BSAF devices 
was to maximize the value of sBL Qmk /  in a given device until perfusion limited antibody 
removal was achieved. Antibody removal rate in the small scale BSAF devices, packed at their 
maximum loading capacity with 3 g of CL-6B beads, fell into the intermediate range with 
6.5/ =sBL Qmk . When this removal rate was compared with the model prediction of antibody 
removal in an optimized state ( sBL Qmk / =10), we concluded that a further increase in sBL Qmk /  
was unwarranted, as antibody removal rate was already approaching the perfusion limited regime 
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(Figure 4-7, dashed line). The next step in BSAF design optimization was to maximize the 
magnitude of Rs VQ /  within a realistic range. In general, blood flow rate is determined based on 
the hemodynamic stability of a patient and usually ranges between 100 and 500 ml/min [83, 137-
139] [27] , and since sQ  only represents a fraction of total blood flow rate, it may not exceed 
250-300 ml/min.  As shown in Figure 4-8, a sQ of approximately 250 ml/min would be required 
to achieve 100% antibody removal in a clinical scale BSAF device ( 5000=RV ml), within two 
hours. Using the mathematical model (equation 4-5) and assuming an average blood flow rate 
( )Q  of 314 ml/min [83], we estimated that the length of the modules should be approximately 25 
cm to achieve a sQ  of 250 ml/min. Subsequently, the minimum mass of CL-6B beads for a full 
scale BSAF device was calculated from our earlier optimization constraint: 6.5/ =sBL Qmk , 
assuming: sQ =250 ml/min and 27.3=Lk  ml/g.min. A blood flow rate of 0.11 ml/min within 
each fiber [137-138] was used to  calculate the total number of fibers in a clinical BSAF device. 
The BSAF inner shell diameter was calculated based on the minimum required volume to 
encompass the required number of fibers and beads in a device. The device dimensions and 
operating parameters for our envisioned clinical BSAF device are summarized in Table 4-4. 
Although the BSAF is designed for direct hemoperfusion, we validated our model using a 
monoclonal antibody capture model instead of whole blood. This simplified system allowed us to 
understand the basic mechanisms underlying antibody capture in BSAF devices independent of 
the various complexities inherent to whole blood perfusion. For example, antibody 
concentrations and affinities for the immobilized A-trisaccharide epitopes naturally vary in 
different blood samples. Monoclonal antibodies are ideal for validation of a mathematical model 
since they provide uniform binding characteristics across multiple experiments. Upon testing the 
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BSAF with whole blood, the fiber hydraulic permeability, first order rate constant and viscosity 
must be re-evaluated and appropriate values must be used in the mathematical model. A simpler 
alternative would be to obtain time course of antibody removal in BSAF devices from various 
blood samples and fit our mathematical model to the averaged normalized concentrations over 
time. We could then estimate the model parameters from the best nonlinear regression fit. Using 
this method, we may be able to obtain average values for the three model parameters in whole 
blood. Nevertheless, the current model provides a basis to efficiently design and evaluate a 
BSAF device with a clinically relevant antibody removal rate.  In Chapter 6.0, we will discuss 
applicability of our mathematical model to antibody capture in BSAF from whole blood. 
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Table 4-4: Design characteristics of a conceptual clinical scale and an appropriately 
scaled down BSAF device. 
 
 
Module Characteristics 
 
Clinical-scale 
 
Small-Scale 
 
Module length (cm) 
 
25 
 
25 
 
Inner shell diameter (cm) 
 
7.6 
 
0.635 
 
Number of fibers 
 
2854 
 
20 
 
Mass of beads (g) 
 
428 
 
3 
 
Blood flow rate (ml/min) 
 
314 
 
2.2 
 
Blood volume (ml) 
 
5000 
 
35 
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5.0  TOWARDS DEVELOPMENT OF BSAF DEVICES WITH INTEGRATED BEAD 
MIXING MECHANISM 
We summarized the many advantages of a sorbent suspension over a packed sorbent column in 
removal of target molecules from blood or plasma (see section 2.5.1). In BSAF devices a sorbent 
suspension in the fiber interstitial space particularly provides two main advantages; the beads in 
suspension are uniformly available for adsorption of the target antibodies, and more importantly, 
the flow resistance in the fiber interstitial space is negligible. Conversely, a tightly packed 
sorbent column within the fiber interstitial space causes significant pressure drop along the axial 
direction in the shell side. As a result, transmembrane pressure decreases and consequently 
Starling flow rate and the overall antibody removal rate in the device decrease as well. As we 
will show in this chapter, our experiments have demonstrated that, to maintain the bead slurry in 
suspension and uniformly distributed within the fiber interstitial space, a bead recirculation 
regimen is required. We observed that in the absence of a bead recirculation mechanism, Starling 
flow continuously pushed the beads toward one end of the device and hence compressed the 
beads into a packed sorbent column. This resulted in reduction of the overall antibody removal 
rate in the BSAF. 
We are interested to maintain the bead recirculation pathway as an integrated unit within 
the device and our efforts are ongoing to design an integrated bead mixing mechanism to 
minimize the external tubing and simplify the device operation. In this chapter we will first 
 105 
address the studies that highlighted the need for a bead recirculation mechanism in BSAF 
devices. We will then describe design, fabrication and testing of a new set of BSAF devices 
which incorporated an inner porous tube to internalize the bead recirculation pathway within the 
device. As we will describe further, these modules provided a simplified prototype of a more 
sophisticated device which will allow bead recirculation and antibody capture to occur 
simultaneously within a single unit.  The efficiency of antibody removal directly from whole 
blood in our fabricated scaled down BSAF prototypes will be addressed in the following chapter. 
5.1 MATERIALS AND METHODS 
5.1.1 Preparation of Affinity Beads 
Synthesized polyacrylamide glycoconjugates (Atri-pNPA30) containing 20 mol% of A-
trisaccharides were covalently attached within the pores of cross linked Sepharose® CL-4B and 
CL-6B beads (Sigma-Aldrich, Louis, MO) according to the methods described before in section 
4.2.1. To ensure consistency between the different batches of modified beads, we measured 
antibody removal capacity and first order rate constant of the modified beads according to the 
methods described in section 4.2.2.  
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5.1.2 Fabrication of the BSAF Modules 
Small scale BSAF modules containing 20 fibers were fabricated as described in section 4.2.3. 
Additionally, another series of BSAF modules with incorporated inner porous tubes were 
fabricated as follows: Polycarbonate tubes (K-mac Plastics, Wyoming, MI) of 25 cm length and 
1.25 cm inner diameter were used as the housing of our BSAF modules. In each case, a circular 
hole (0.5 mm) was drilled in the outer surface of the shell case at 1 cm from one end of the tube 
and a polycarbonate luer fitting (Value Plastics, Fort Collins, CO) was glued to the hole using 
UV light curing adhesive (DYMAX, Torrington, CT). A porous tube was fabricated by drilling 
circular holes of 1 cm diameter equally spaced at approximately 2 cm apart from one another in 
the peripheral area of a second cylindrical polycarbonate tube of 0.3 cm inner diameter and 25 
cm length. Eighty matted polyethersulfone microfiltration hollow fiber membranes (MicroPES®, 
Membrana GmbH, Wuppertal, Germany) of 0.03 cm inner diameter and 0.01 cm wall thickness 
were wrapped around this tube. The tube was then placed in the center of the BSAF shell case in 
a manner which left approximately 3 cm of fibers protruding from each end of the housing and 2 
cm of the inner tube protruding from only one end of the case.  Both ends were filled with hot 
glue, and the excess glue was tomed with a razor blade once hardened. Polycarbonate caps with 
luer fittings were fabricated and attached to all three outlet ports of the device using UV light 
curing adhesive. 
The design parameters of BSAF modules with inner porous tubes (including the module 
length, inner shell diameter, the number of fibers and the mass of beads) and the operational 
parameters (including reservoir volume and flow rate) were all appropriately scaled up in 
relation to the corresponding values of our small scale BSAF modules, which contained 20 
fibers. Additionally, these values were appropriately scaled down in relation to the corresponding 
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values of our conceptual clinical scale BSAF devices. Therefore, hereupon we will refer to our 
fabricated BSAF modules with inner porous tubes as the intermediate scale devices and our 
fabricated small modules, containing 20 fibers, will be referred to as small scale devices. Table 
5-1 summarizes the device dimensions and operational parameters of our conceptual clinical 
scale BSAF devices, as well as the corresponding values of our scaled down (small scale and 
intermediate scale) modules. 
5.1.3 In-Vitro Antibody Capture Experiments in Small Scale BSAF Devices 
We performed a series of experiments to determine the effect of bead recirculation on antibody 
removal rate in BSAF devices. For measurement of antibody capture rate in BSAF devices in the 
absence of bead recirculation, the shell side of small scale BSAF devices was initially loaded 
with 3.0 g of modified CL-4B or CL-6B beads as described in section 4.2.5. Then, we connected 
the two shell ports of the modules with a short piece of Tygon® tubing, primed with PBS buffer. 
Subsequently, the tubing was connected to a Masterflex peristaltic pump and the flow rate was 
set at 6 ml/min. Bead recirculation was performed for 10 minutes before initiating antibody 
capture experiments which resulted in uniform bead distribution throughout the module length. 
Subsequently, bead recirculation was stopped and the two shell ports were capped and antibody 
capture experiments were performed as described in section 4.2.5.  
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Table 5-1: Device dimensions and operational parameters in our conceptual clinical 
scale, intermediate and small scale devices. 
 
Module Characteristics Clinical Scale 
Intermediate 
Scale 
Small 
Scale 
Module length (cm) 25 25 25 
Inner shell diameter (cm) 7.6 1.25 0.635 
Inner porous tube diameter 
(cm) 1.82 0.3 N/A 
Number of fibers 2854 80 20 
Mass of beads (g) 428 11 3 
Blood flow rate (ml/min) 314 8.8 2.2 
Bead recirculation flow rate 
(ml/min) 642 18 6 
Blood volume (ml) 5000 135 35 
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5.1.4 In-Vitro Antibody Capture Experiments in BSAF Modules with Inner Porous 
Tubes 
Before initiating each antibody capture experiment, the shell compartment of a BSAF device 
with an inner porous tube was loaded with 11 g of modified CL-6B beads as follows: A beaker 
containing a 50% bead slurry in PBS (pH 7.4) buffer (Fisher Scientific, Pittsburgh, PA) was 
connected via a luer fitting to the shell of the BSAF using Tygon® tubing (Cole-Parmer, Vernon 
Hills, IL).  A 1 ml polypropylene Rezorian cartridge (Supelco, St Louis, Mo) equipped with a 
polyethylene filter was connected to the central porous tube outlet port of the BSAF. The bead 
slurry was then pumped via a Masterflex peristaltic pump (Cole-Parmer, Vernon hills, IL) into 
the shell side at a flow rate of 10 ml/min, while excess liquid was filtered through the fiber and 
inner porous tube outlet ports. The Rezorian cartridge was then disconnected and the shell inlet 
port was connected to the central porous tube outlet port with a piece of Tygon® tubing, primed 
with PBS buffer. Subsequently, the tubing was connected to a Masterflex peristaltic pump and 
the flow rate was set at 18 ml/min. 
The monoclonal antibody (mAb) solution was prepared as described in section 4.2.5. The 
fiber side inlet and outlet ports were connected to a reservoir containing 135 ml of mAb solution 
using Tygon® tubing. The antibody solution was recirculated through the BSAF module at a 
flow rate of 8.8 ml/min by a Masterflex pump attached to the inlet tubing. The reservoir solution 
was stirred throughout the experiment. Samples were taken from the reservoir at times 0, 5, 10, 
15, 30, 60, 90 and 120 minutes and assayed for antibody concentration using enzyme linked 
immunosorbent assay (ELISA) as described before [116].  
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Antibody concentrations over time were normalized to an initial concentration of 10 
µg/ml. An average normalized concentration value at each time point was calculated ( 2=n ). 
Antibody capture rates in the BSAF, as predicted by the model in equation (4-10), were 
generated based on the parameter values summarized in Table 5-2. Each data set was compared 
to the model prediction of antibody capture rate by computing a coefficient of determination, 
2R [140], value : 
tot
err
SS
SSR −= 12 , where errSS   is the sum of squared errors between the 
experimental  values and the values predicted by the model for each time point and totSS  is the  
total sum of squares of the experimental values. 
5.2 RESULTS 
5.2.1 Evaluation of the Effect of Bead Recirculation on Antibody Removal Rate in BSAF 
Devices 
Figure 5-1 compares antibody capture rate in BSAF devices, packed with 3.0 g of modified CL-
4B beads, in presence (+) or absence (-) of a bead recirculation regimen. Similarly, Figure 5-2 
shows the effect of bead recirculation on antibody capture rate in BSAF devices packed with 3.0 
g of modified CL-6B beads. The 2R  values in the absence of bead recirculation were 0.3091 and 
0.5333 in devices packed with CL-4B and CL-6B beads, respectably. Whereas, in presence of 
bead recirculation, there was better agreement between experimental clearance data and the 
model predictions ( 2R  values were 0.9765 and 0.9793, for CL-4B and CL-6B, respectively). 
Figure 5-3 shows the effect of bead recirculation on antibody removal rate in small scale BSAF 
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devices, in which all operational parameters were appropriately scaled down from a “clinical” 
BSAF device. Similar to the previous cases, antibody removal rate was lower in the absence of 
bead recirculation ( 2R values were 0.8528 and 0.9112 in the absence and presence of bead 
recirculation, respectively). 
The bead slurry position within the BSAF modules, in presence and absence of bead 
recirculation, was visualized by staining the beads with a blue dye solution prior to loading the 
beads in the fiber interstitial space. Figure 5-4 shows that the stained beads (blue) are uniformly 
distributed throughout the module when beads are continuously recirculated. Figure 5-5 shows 
the same stained beads in a BSAF device in the absence of bead recirculation. The stained beads 
gradually moved toward one end of the device and formed a compressed sorbent bed throughout 
the module end (Figure 5-5). 
5.2.2 In-Vitro Antibody Capture in BSAF Devices with Integrated Inner Porous Tubes  
Figure 5-6 shows a schematic of the recirculation loop used in our in-vitro antibody capture in 
BSAF devices with integrated inner porous tubes. The mAb capture experiments were performed 
to evaluate the efficiency of our bead recirculation loop in maintaining uniformly mixed and well 
distributed bead slurry in the fiber interstitial space of BSAF devices. Figure 5-7 shows the 
results of antibody clearance over time in two different antibody capture experiments (data 
points are shown as average of two experiments). As shown in Figure 5-7, there was good 
agreement between the model predictions and our experimental results )9699.0( 2 =R ; this 
indicated that a uniformly distributed bead slurry was maintained throughout the modules in the 
BSAF devices with inner porous tubes. 
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Figure 5-1: Effect of bead recirculation on clearance. Antibody clearance was 
measured in presence (+) or absence (-) of bead recirculation. 
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5.3 DISCUSSION 
We demonstrated that to achieve an antibody removal rate in agreement with the model 
prediction, it was crucial to maintain a well mixed and uniformly distributed bead slurry in the 
interstitial fiber space. In the absence of a bead mixing mechanism, antibody removal rates 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-2: Effect of bead recirculation on clearance. Clearance was 
measured in presence (+) or absence (-) of bead recirculation. 
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were lower than predicted by our mathematical model due to the Starling flow continuously 
pushing the beads toward one end of the device. Incorporation of a simple bead recirculation 
loop, as shown in Figure 5-4, provided a mechanism to maintain uniformly distributed bead 
slurry throughout the module length. However, this simple bead recirculation system is not an  
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 5-3: Effect of bead recirculation on clearance. Clearance was measured in 
presence (+) or absence (-) of bead recirculation. 
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ideal choice for a clinical full scale BSAF module, as our goal is to maintain the bead 
recirculation pathway as an integrated unit within the device, to minimize the external tubing and 
simplify device operation. This goal was achieved to some extent in this study by replacing the 
previous bead recirculation loop with a built-in porous tube which was connected to a 
neighboring shell port through a very short piece of tubing and a peristaltic pump (Figure 5-6). 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-4: Visualization of the bead slurry position within a BSAF module, in 
presence of bead recirculation. The stained beads (blue) are uniformly distributed 
throughout the module, when beads are continuously recirculated. 
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Thus, the majority of the external tubing was eliminated in this design. Based on our in-vitro 
antibody capture data in the new BSAF modules with inner porous tubes, we concluded that a 
well distributed bead slurry was maintained throughout the module length. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-5: Visualization of the bead slurry position within a BSAF module, 
in the absence of bead recirculation. The stained beads gradually moved toward one 
end of the device and formed a compressed sorbent bed throughout the module end. 
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In addition to modification of the bead recirculation pathway, the BSAF modules with 
inner porous tubes in this study were appropriately scaled up from the small scale BSAF devices 
that we had tested in Chapter 4.0. The same antibody removal rate was observed in our 
fabricated small scale and intermediate scale modules. Thus we showed that we could use our 
mathematical model to scale up BSAF devices and accurately predict antibody capture rate in the 
clinical scale modules.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-6: A schematic of the recirculation loop used in our in-vitro antibody 
capture in BSAF devices with integrated inner porous tubes. 
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We envision that the future generations of the BSAF devices would use the same 
principle to maintain efficient bead recirculation but in a more integrated fashion. Figures 5-8 
and 5-9 depict a conceptual integrated BSAF device which will allow bead recirculation and 
antibody capture to occur simultaneously within a single unit. The plasma pump and the external  
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Figure 5-7: Monoclonal anti-A antibody (mAb) capture data and respective model 
prediction of time course of mAb removal in BSAF devices. 
 
tubing, which were used for bead recirculation in this study, will be replaced with an integrated 
centrifugal pump. Through continuous rotation of an impeller, the centrifugal pump will provide 
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the energy to recirculate the bead slurry internally within the module. The centrifugal pump will 
be placed in a cavity at one end of the device (the cavity is not shown for simplicity). As the  
 
 
 
Figure 5-8: A schematic of the side view of a conceptual fully integrated BSAF 
device with an inner porous tube and an integrated centrifugal pump. 
 
 
blades of the impeller rotate, the volume of the liquid between the blades expands and induces a 
sucking force to draw the bead slurry and plasma along the rotating axis through the outlet port 
of the inner porous tube. The rotating impeller radially accelerates the bead slurry outward and 
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expels the fluid into the downstream tubing, where it is pumped back into the shell (Figure 5-9).  
Continuous rotation of the impeller provides a smooth, bead recirculation flow throughout the 
module length. Only one set of external pump/tubing will be required to recirculate blood 
through the BSAF modules.  
A clinical BSAF device will be pre-packed with the bead slurry, and both inlet and outlet 
blood access lines will be compatible with normal hemodialysis tubing lines. Overall, the blood 
circuit during antibody removal in BSAF devices will be similar to a normal blood circuit set up 
during a hemodialysis session. Therefore antibody removal in BSAF devices could be performed 
in the clinical facilities which are already equipped with hemodialysis machinery. Antibody 
removal takes approximately two hours and one single BSAF device may be sufficient to remove 
antibodies from whole blood volume of an adult patient.  
Antibody capture data in our fabricated BSAF prototypes with inner porous tubes have 
already provided us with a “proof of concept” that our envisioned integrated bead mixing 
mechanism will maintain the bead slurry in a uniformly distributed state. Future work should 
focus on experimental evaluation and characterization of the conceptualized integrated bead 
mixing mechanism for BSAF devices. In the following chapter, we will test antibody removal in 
our BSAF prototypes directly from whole blood. 
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Figure 5-9: A schematic of the cross sectional side view of a conceptual fully integrated 
BSAF device with an inner porous tube and an integrated centrifugal pump. 
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Table 5-2: Description of the parameters of the mathematical model and the 
respective values, used to generate the model predictions of antibody capture rate in BSAF 
with inner porous tube. 
 
Parameter name Description Baseline value 
di Fiber inner diameter  0.03 
L Module length  25 
mB Mass of beads (g) 11 
K 
Fiber hydraulic permeability 
(cm/mm-Hg.min) 
0.056 
kL 
First order rate constant 
(ml/g.min) 
3.27 
µ Viscosity (mm-Hg .min) 1.25×10-7 
Q 
Volumetric flow rate 
(ml/min) 
8.8 
VR Reservoir volume (ml) 135 
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6.0  EVALUATION OF ANTI-A ANTIBODY CAPTURE FROM WHOLE HUMAN 
BLOOD IN INTEGRATED BEAD AND FIBER ANTIBODY FILTERS 
In Chapter 4.0, we developed a simple mathematical model to predict antibody removal rate in 
BSAF modules based on key design and operational parameters. We used this model as a guide 
to design human patient-sized BSAF devices. We also fabricated scaled down prototypes of our 
conceptual clinical scale BSAF (small scale devices) and demonstrated that recirculation of 
monoclonal anti-A antibody in buffer solution through our scaled-down prototypes resulted in 
100% antibody removal within two hours. In chapter 5.0, we scaled up from our small scale 
modules and fabricated intermediate scale devices (see Table 5-1) and modified the bead 
recirculation pathway to further integrate the bead mixing mechanism within the BSAF devices. 
The experimental work in Chapter 5.0 ensured both efficacy of our modified bead recirculation 
pathway and the capability of our mathematical model to scale up.   
In this study, our goal was to evaluate the in-vitro anti-A antibody removal in our 
intermediate scale BSAF modules using direct hemoperfusion. We set up appropriately scaled 
down in-vitro blood recirculation loops, similar to that used in Chapter 5.0, and tested anti-A 
antibody capture in BSAF devices directly from whole human blood samples. We evaluated the 
capability of our BSAF devices to reduce IgM and IgG anti-A antibody titers in blood within two 
hours. Antibody capture specificity and dilution effects were evaluated by monitoring initial and 
final IgG and IgM anti-B antibody titers, total blood protein concentration and blood hematocrit. 
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Plasma free hemoglobin (PFHb) level was monitored throughout antibody capture experiments 
to detect possible device-induced hemolysis.  
6.1 MATERIALS AND METHODS 
6.1.1 In-Vitro Antibody Capture  
Polyacrylamide glycoconjugates (Atri-pNPA30) containing 20 mol% of A-trisaccharides were 
covalently attached within the pores of cross linked Sepharose® CL-6B beads (Sigma-Aldrich, 
Louis, MO) as described in section 4.2.1.  BSAF modules with inner porous tubes were 
fabricated as described in section 5.1.2. The modules were loaded with 11 g of modified beads as 
described in section 5.1.4. The bead recirculation flow rate was set at 18 ml/min.   Experiments 
were then performed to quantify antibody capture from fresh human blood samples in BSAF 
devices as follows: with the approval of the University of Pittsburgh Institutional Review Board 
(IRB), five blood samples (3 samples of  type O and 2 samples of type B) were drawn from 
healthy, non-pregnant consenting donors over age 18.  In each case, 135 ml of blood was drawn 
within 1 hour before initiation of an antibody capture experiment. Blood samples were 
individually collected in 150 ml dry blood collection bags (Jorgensen Laboratories Inc, Loveland 
Co), and 0.106 M sodium citrate anticoagulant solution (Fisher Scientific, Pittsburgh, PA) was 
added to each bag at a volumetric ratio of 1:10. During antibody capture experiments, the blood 
bags were placed in an Isotemp 202S water bath (Fisher Scientific, Pittsburgh, PA) to maintain 
blood temperature at 37 oC. The fiber side inlet and outlet ports were connected to the ports on 
the blood bags using Tygon® tubing. Blood was recirculated through the BSAF modules at a 
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flow rate of 8.8 ml/min by a Masterflex pump attached to the inlet tubing. Air was removed from 
the system while the capture loop was primed with blood. Blood samples were taken from a 
sampling port on the blood bags at time points 0, 15, 30, 75 and 120 minutes. Plasma was 
separated from blood cells by immediately spinning blood samples in a Fisher Scientific 
Centrific 228 centrifuge (Fisher Scientific, Pittsburgh, PA) for 30 minutes.  All plasma samples 
were stored at -80oC if not analyzed immediately. Figure 6-1 shows the recirculation loop in 
antibody capture from whole blood. Blood inlet/outlet and bead/plasma inlet/outlet ports are 
shown in  Figure 6-2. 
6.1.2 Blood Analysis 
Blood typing and measurement of anti-A/B antibody titers was performed according to 
standard blood bank procedures [117]. Briefly, plasma samples were serially diluted in 0.9% 
saline solution (Fisher Scientific, Pittsburgh, PA). All serial dilutions were given a consecutive 
titer step number. For example, a dilution of 1:1 corresponded to titer step 1, dilution of 1:2 
corresponded to titer step 2, dilution of 1:4 corresponded to titer step 3 and so forth. One drop of 
A1 or B reference red blood cells (Immucore Inc., Norcross, GA) was added to each test tube 
and the tubes were spun for 1 minute at 3300 rpm. Tubes were then examined macroscopically 
for agglutination of A1 and B red blood cells, respectively. IgM anti-A and anti-B titers were 
recorded as the reciprocal of the largest dilutions that agglutinated A1 and B reference blood 
cells, respectively.  Subsequently, IgG anti-A and anti-B titers were measured in the following 
manner: after addition of one drop of A1 or B reference red blood cells to serial dilutions of 
plasma, test tubes were incubated at 37oC for one hour. Each test tube was then washed three 
times with 0.9% saline solution and after each washing step the supernatant was decanted. Two 
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drops of anti-IgG murine monoclonal antibody (Immucor-Gamma Biologicals Inc, Houston, TX) 
was added to the dry red blood cell pellet in each test tube and test tubes were centrifuged at 
3300 rpm for 15 seconds. Hemagglutination was read macroscopically and IgG anti-A and anti-B 
titers were recorded as the reciprocal of the largest dilutions with positive agglutination of blood 
cells.  
 
 
 
 
 
 
 
 
 
Figure 6-1: An actual experimental set up in blood recirculation through a BSAF 
device. 
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Hematocrit was measured in blood samples collected at time points 0 and 120 minutes, as 
described before [141]. Briefly, blood samples were collected in heparinized microcapillary 
tubes (Fisher Scientific, Pittsburgh, PA) and were spun in an IEC MB microhematocrit 
centrifuge (Damon IEC Division, Needham Heights, MA) for 5 minutes.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6-2: Blood inlet/outlet and bead/plasma inlet/outlet ports in blood 
recirculation through a BSAF device. 
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Hematocrit was reported as the ratio of the length of the packed erythrocytes to the total length 
of samples in the capillary tubes [141]. Total protein concentration was measured using Bradford 
protein assay (Pierce Protein Research Products, Rockford, IL). Plasma free hemoglobin (PFHb) 
level was measured as described elsewhere [142]. Briefly, plasma samples were spun at 10000 
rpm in VWR Galaxy 7 microcentrifuge (VWR International, West Chester, PA) for 15 minutes. 
Light absorbance by supernatant was measured at 540 nm using a Genesys 5 UV 
spectrophotometer (Thermo Spectronic, Somerset, NJ). Light absorbance was converted to PFHb 
concentration, using reference values of known concentrations of bovine hemoglobin solution 
[143]. The normalized index of hemolysis (NIH) was calculated as previously described [144]: 
100
)100(
.
.
. Ht
tQ
VHbNIH R −∆= , where Hb∆  is the change in PFHb level over time, t  and RV  is the 
blood volume in the reservoir, Ht  is blood hematocrit, and Q  is the volumetric flow rate in a 
BSAF device.       
6.1.3 Statistical Analysis     
The values of IgM anti-A antibody titers over time were normalized to the corresponding initial 
titer in each experiment. An average normalized titer value at each time point was calculated 
between five blood experiments (n=5). A  two-sample t-test was used to test the significance of 
the differences between the normalized IgM concentration values at times 15, 30 and 120 
minutes in antibody capture from monoclonal antibody solution (n=2, data points were shown 
previously in Figure 5-7) and whole blood (n=5). A paired two-sample t- test was used to test 
the significance of differences between initial and final values of PFHb and total protein 
concentration, respectively (n=5). The null hypothesis in all cases was rejected for 05.0≤p . 
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6.2 RESULTS 
Antibody removal from whole blood was evaluated by measurement of changes in blood IgM 
and IgG anti-A antibody titers within two hours. We also evaluated antibody capture specificity 
and dilution effect by measurement of changes in anti-B antibody titers, total blood protein 
concentration and hematocrit. Figure 6-3 shows the time course of IgM anti-A antibody capture 
in BSAF devices from blood and from monoclonal antibody solution (mAb). We did not observe 
a significant difference in antibody removal when we compared whole blood with the mAb 
solution ( 42.0=p , 0.96 and 0.08 at times 15,  30 and 120 minutes, respectively). Table 6-1 
summarizes the results of blood analysis data from samples collected in five different 
experiments at times 0 and 120 minutes. Overall, we observed a significant reduction in IgM 
)001.0 , 5%96( <± p , and IgG )05.0 , 18%81( <± p  anti-A antibody titers. Blood concentration 
of IgM anti-A antibodies was reduced by 4.2±0.8 titer steps, dropping from an initial titer range 
of 8-32 to a final titer range of 0-2. Blood concentration of IgG anti-A antibodies was reduced at 
a slightly lower rate, by 2.8±1.1 titer steps, dropping from an initial titer range of 2-256 to a final 
range of 1-32. No change in IgG anti-B antibody titers was observed and nonspecific loss of IgM 
anti-B antibodies was not significant (reduced only by 0.7±0.6 titer steps, 36.0=p ). 
Figure 6-4 shows total plasma protein concentration in five different blood samples over 
time. A paired two-sample t- test was used to test the significance of differences between initial 
and final values of total protein concentration, in five different experiments (n=5). We did not 
observe a significant difference between the values of plasma protein concentration at time 
points 0 and 120 minutes ( 22.0,5 == pn ). Figure 6-5 shows PFHb concentration in five 
different blood samples over time. A paired two-sample t- test was used to test the significance 
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of differences between the initial and final values in five different experiments (n=5). No 
significant difference was observed between the PFHb levels at time points 0 and 120 minutes 
( 25.0,5 == pn ). The values of normalized index of hemolysis (NIH) for two hours of blood 
recirculation through BSAF devices,  in five experiments, are summarized in Table 6-1. Blood 
hematocrit remained unchanged in each experiment. 
 
0
0.2
0.4
0.6
0.8
1
0 30 60 90 120
t (min)
C/
C i
blood mAb
 
Figure 6-3: IgM anti-A antibody capture data from whole blood and from monoclonal 
antibody solution (mAb). 
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6.3 DISCUSSION 
Removal of anti-A/B antibodies from blood in the peri-transplantation period significantly 
reduces the risk of humoral mediated rejection of  
an ABO-incompatible transplanted organ [3]. We are developing an extracorporeal antibody 
filter (BSAF) to specifically remove anti-A/B antibodies directly from whole blood. BSAF 
devices are cartridges containing microfiltration hollow fibers with antibody capturing beads 
continuously recirculating in the fiber interstitial spaces. We used our mathematical model of 
antibody removal in BSAF devices and in-vitro anti-A antibody capture from monoclonal 
antibody solution to design BSAF modules capable of depleting up to 100% of reservoir anti-A 
antibody concentration within two hours. However, since the model was primarily developed and 
validated for a simplified case of antibody removal from monoclonal antibody solution, further 
evaluation was necessary to show applicability of our BSAF devices in antibody removal 
directly from whole blood. In this study we set up in-vitro blood recirculation loops with 
parameters scaled down in equal proportions from typical clinical values and tested anti-A 
antibody removal rate. Our studies showed that IgM and IgG anti-A antibody titers in blood were 
specifically decreased by 96±5% and 81±18%, respectively, within two hours. 
From a clinical standpoint, most centers target a pre-transplantation IgM anti-A/B 
antibody titer of 1:8 or below [20]. On the other hand, in some studies,  IgG anti-A/B antibody 
titers of 1:32 or even higher did not adversely affect the result of ABO-incompatible 
transplantation [20, 84]. In our study, despite the wide range of initial antibody titers, we were 
able to reduce both IgM and IgG anti-A antibodies to 1:2 and 1:32 or below, respectively. Hence, 
our BSAF devices met our goal in achieving clinically acceptable pre-transplantation anti-A 
antibody titers. We understand that the final antibody titers and the duration of antibody capture  
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Figure 6-4: Total plasma protein concentration over time in 5 different blood 
samples. 
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may vary in an in-vivo setting. Patients with an initial antibody titer greater than 1:128 and a 
high titer rebound capability may require more than one session of antibody removal to meet the 
target antibody titer of 1:8 or below. 
In this study, the concentration of IgM and IgG anti-A antibodies was reduced by an 
average of 4.2±0.8 and 2.8±1.1 titer steps, respectively. Thus, compared to other previously 
developed anti-A/B specific immunoadsorption devices, our BSAF modules showed comparable 
capability in reducing antibody titers. Rieben et al. reported an average of 4 titer step reduction in 
IgM anti-A antibodies in plasma recirculating through BioSorbent A and B columns [24]. 
Rydberg et al. showed 2 and 4 titer step reduction in IgM and IgG anti-A antibodies, 
respectively, during in-vitro plasma perfusion through Glycosorb® columns [25]. However, 
during each session of in-vivo plasma immunoadsorption through Glycosorb® devices, both IgG 
and IgM anti-A antibody titers were dropped by an average of 2 titer steps [93]. Additionally, 
similar to BioSorbent A [24] and Glycosorb® columns [25], our BSAF devices selectively 
removed anti-A antibodies and did not cause significant change in total plasma protein 
concentration. Previously, Rieben et al. showed negligible nonspecific adsorption of 
immunoglobulins on BioSorbent A and B columns [24]. In biocompatibility testing of 
Glycosorb® columns, Rydberg et al. reported no significant change in total serum albumin or 
total IgG, IgA, or IgM levels [25].  Although antibody removal capacity of the BSAF is 
comparable to these columns, the main advantage of the BSAF is its simplicity.  Unlike 
conventional immunoadsorption columns, a separate plasmapheresis unit is not required prior to 
immunoadsorption. Eliminating the need for plasma separation simplifies extracorporeal 
perfusion and eliminates the hemodynamic instabilities that can be associated with 
plasmapheresis. 
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Figure 6-5: Plasma free hemoglobin (PFHb) concentration over time in 5 different 
blood samples. 
 
 
 
 
We observed some inconsistencies between the numbers of titer steps reduced in different 
blood samples. For example, an initial anti-A antibody titer of 1:16 was reduced once by 5 titer 
steps and by only 3 titer steps in another blood sample. An initial antibody titer of 1:32 was 
reduced by 6 titer steps, whereas another blood sample with a lower initial antibody titer of 1:16 
was reduced by 5 titer steps in another case. As all antibody capturing beads in this study were 
modified and prepared in one batch, variations in antibody binding capacity of the beads are not  
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Table 6-1: Analysis of initial (t=0) and final (t=120) blood samples in five different 
experiments. 
 
Sample 
Number/ 
Blood 
Type 
Anti-A 
(IgM) 
titer 
initial / 
final 
Anti-A 
(IgG) titer 
initial / 
final 
Anti-B 
(IgM) 
titer 
initial / 
final 
Anti-B 
(IgG) 
titer 
initial / 
final 
Hematocrit 
(%) 
initial / 
final 
Plasma Free 
Hemoglobin 
(mg/dl) 
initial / 
final 
Total 
Protein 
(g/dl) 
initial / 
final 
Normalized 
Index of 
Hemolysis 
(NIH) 
(mg/dL) 
1/B 1:8/0 1:2/1:1 N/A N/A 25/25 2.5/3.1 3.4/ 2.9  0.06 
2/B 1:16/0 1:16/1:1 N/A N/A 37/37 10.1/8.1 3.1 / 2.8  -0.16 
3/O 1:32/1:2 1:256/1:32 1:16/1:8 1:32/1:32 42/42 4.2/5.0 3.3 / 2.9  0.05 
4/O 1:16/1:2 1:64/1:8 1:1/0 1:8/1:8 39/39 4.0/9.5 3.0 / 3.1  0.43 
5/O 1:32/1:1 1:64/1:8 1:16/1:16 1:64/1:64 43/43 0.4/4.5 3.0/ 3.2  0.3 
 
 
 
 
responsible for the observed inconsistencies in antibody removal patterns from various blood 
samples. Furthermore, the BSAF modules were designed to maintain an excess of anti-A 
antibody binding sites compared to the normal range of antibody concentrations in blood. One 
possible explanation is that the remaining anti-A antibody population in blood samples simply 
did not recognize or had low affinity for A-trisaccharide epitopes. Some previous studies have 
suggested that a small population of anti-A antibodies require a fourth sugar in the core 
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composition of A-tetrasaccharide epitopes for a high affinity binding interaction [145]. Complete 
removal of all anti-A antibodies from blood samples may therefore require use of a combination 
of A-trisaccharide and A-tetrasaccharide polyacrylamide glycoconjugates as the synthetic 
antigens in our device. Additionally, BSAF devices were more effective in removing IgM than 
IgG isotype.  This difference could be attributed to the capability of IgM anti-A antibodies to 
form multivalent and hence more stable binding interactions with closely spaced immobilized 
Atrisaccharide-polyacrylamide antigens. IgM antibodies also form more stable complexes with 
C1 molecules (a prerequisite of complement activation) and are therefore considered the most 
potent antibody isotype in activation of the complement cascade [3].   
Because the BSAF is perfused directly with whole blood, it was important to show that 
blood flow through our devices was not associated with a significant level of hemolysis.  
Although in our experiments the concentration of PFHb in different blood samples changed over 
time, a statistical analysis showed no significant change between initial and final values over all 
five blood experiments. The maximum increase in the PFHb concentration after two hours of 
blood recirculation through the BSAF devices was observed in blood sample #4, which showed a 
5.5 mg/dL increase in PFHb concentration after two hours. Approximately 5 mg/dL/hr of PFHb 
can be removed by reticuloendothelial system in adult patients [146] and in humans a renal 
clearance of 12 mg/dL/hr is possible [146]. Therefore, the levels of increase in PFHb 
concentrations in this study were within the physiologically tolerable range [146]. Additionally 
the averaged normalized index of hemolysis (NIH) for two hours of blood recirculation through 
BSAF modules was 0.14 mg/dL (NIH values ranged between -0.16 and 0.43), which was   
comparable to the previously reported levels of  NIH values for other blood contacting medical 
devices (typically <0.2 mg/dL) [144, 147]. In summary our study showed no significant evidence 
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of hemolysis or change in total plasma protein concentration. A more extensive evaluation of the 
biocompatibility of the BSAF, which will involve a larger number of blood samples (>10), needs 
to be performed in our future studies. Previously Rieben et al. [24] and Rydberg et al. [25] 
established the biocompatibility of plasma immunoadsorption in Biosorbent A and B and 
Glycosorb® columns, respectively.  The BSAF is similar to these columns because only plasma 
comes into contact with the antibody adsorbing beads, which are the same materials found in 
both Biosorbent A and Glycosorb columns. Therefore, we would expect that BSAF devices show 
comparable biocompatibility data to these devices.  
We observed close agreement between antibody capture data from whole blood and from 
mAb solution. This was contradictory to our approximation of 20-25% increase in Starling flow 
rate for blood flow through BSAF modules, compared to flow of mAb solution. One possible 
explanation is that fiber hydraulic permeability decreases during whole blood flow through the 
fibers, compared to flow of the monoclonal antibody solution. A decrease in fiber hydraulic 
permeability during whole blood flow has been linked to protein deposition and adherence of 
platelets and leukocytes on to the membranes [148]. As we did not observe a significant 
difference in total protein concentration in our studies, we do not believe that protein deposition 
would have been responsible for a decrease in fiber hydraulic permeability. Conversely, platelet 
adhesion to the fibers has been reported in blood flow through membranes when blood is not 
heparinized [148]. Scanning electron microscopy on the luminal surfaces of the fiber could 
detect adhered platelets and further confirm this theory. Additionally, direct measurement of 
model parameters (including fiber hydraulic permeability, first order rate constant and viscosity) 
in blood perfusion through BSAF devices could show the applicability of our developed 
mathematical model to a whole blood system.   
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In summary, we have developed a new antibody filtration device containing 
microfiltration fibers with antibody capturing beads integrated within the interstitial fiber space 
(BSAF device). The BSAF was capable of selectively removing clinically relevant levels of 
blood group antibodies from blood in a two hour time period and in a simple one step process. In 
our future studies we will establish the efficacy and biocompatibility of the BSAF in an in-vivo 
set up.  
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7.0  CONCLUSIONS 
1. We conjugated blood group A-trisaccharide antigens to high (1000-2000 kDa) and low (30-
50 kDa) molecular weight polyacrylamide spacers. The glycoconjugate interactions with 
anti-A antibodies were studied using surface plasmon resonance. The high molecular weight 
glycoconjugate (Atri-PAA1000-biotin) enhanced antibody binding capacity by two to three 
fold compared to the low molecular weight conjugate (Atri-PAA30-biotin), whereas varying 
the carbohydrate content in Atri-PAA1000-biotin (20 mol% or 50 mol%) did not affect 
antibody binding capacity of the glycoconjugate. We concluded that with this estimated 
increase in capacity, a fiber based SAF device with a surface area of about 1.5 to 2 m2  would 
provide sufficient capacity for 100% antibody capture from blood in a single device. 
2. We introduced an antibody filtering device based on integrated microfiltration fibers with     
affinity beads distributed in the interstitial fiber space. We developed a simple mathematical 
model to guide the choice of key design and operational parameters for a clinical BSAF 
device.  The model demonstrated that for a given flow rate and reservoir volume, antibody 
removal rate in a BSAF was dependent on the magnitude of a lumped parameter, BLmk / sQ . 
This term characterizes the ratio of antibody uptake rate by the beads to the Starling flow rate 
in the device. Three distinct antibody removal regimes were observed with the following 
approximate boundaries: diffusion limited ( 1/ ≤sBL Qmk ), intermediate ( 10/1 << sBL Qmk ) 
and perfusion limited ( 10/ ≥sBL Qmk ). In diffusion limited regime ( 1/ ≤sBL Qmk ) antibody 
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removal rate primarily depends on antibody diffusion to the binding sites within the porous 
beads. Hence, antibody removal rate in the diffusion limited regime increases substantially as 
sBL Qmk /  increases, but changes insignificantly in relation to an increase in Starling flow rate 
relative to the reservoir volume  ( Rs VQ / ). Antibody removal is perfusion limited  when 
10/ ≥sBL Qmk . In a perfusion limited regime antibody removal rate is solely dependent on 
the magnitude of Starling flow rate relative to the reservoir volume ( Rs VQ / ). No significant 
increase in the antibody removal rate is expected by further increasing the magnitude of 
sBL Qmk /  in a perfusion limited regime. An intermediate regime ( 10/1 << sBL Qmk ) is 
distinguished in which antibody removal rate is affected by a combination of antibody 
diffusion and Starling flow rate in the device.  
3. Key model predictions were in close agreement with experimental data obtained in in-vitro 
monoclonal anti-A antibody capture from buffer solution in BSAF devices. Additionally, the 
model provided a good approximation of antibody removal rate from whole blood. 
4. We used the model to conceptually design a BSAF device capable of a clinically relevant 
rate of anti-A removal. Small and intermediate size BSAF devices (both appropriately scaled 
down from the “clinical” BSAF) were fabricated and tested in capture of anti-A from a buffer 
solution.  Both sets of devices depleted 100% of reservoir anti-A antibody concentration 
within two hours. 
5. We set up in-vitro blood recirculation loops with parameters scaled down from clinically 
relevant values and tested anti-A antibody removal from whole human blood in BSAF 
devices. A significant reduction in IgM )001.0 , 5%96( <± p , and IgG )05.0 , 18%81( <± p  
anti-A antibody titers was observed within two hours. Overall, we observed a drop of 4.2±0.8 
and 2.8±1.1 titer steps in IgM and IgG anti-A antibody titers, respectively. No significant 
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change in hematocrit, total plasma protein concentration, plasma free hemoglobin and anti-B 
antibody levels was observed. The normalized index of hemolysis (NIH) was 0.14±0.23 
mg/dL. In conclusion, BSAF devices effectively, specifically and safely removed anti-A 
antibodies directly from whole blood. 
6. We demonstrated that to achieve an antibody removal rate in agreement with the model 
prediction, it was crucial to maintain a well mixed and uniformly distributed bead slurry in 
the interstitial fiber space. In the absence of a bead mixing mechanism, antibody removal 
rates were slower than predicted by our mathematical model due to the Starling flow 
continuously pushing the beads toward one end of the device. We fabricated BSAF modules 
with integrated inner porous tubes and tested these modules in capture of anti-A antibodies. 
The BSAF modules with inner porous tubes were simplified prototypes of our envisioned 
integrated BSAF devices. Antibody capture data in these modules provided the “proof of 
concept” for our proposed BSAF devices with integrated bead mixing mechanism.  
7. Future work should focus on experimental evaluation and characterization of the 
conceptualized integrated bead mixing mechanism for BSAF devices. 
8. The work presented here may be easily applied to design blood purification devices for 
removal of other biomolecules from blood. Examples of such applications are in treatment of 
autoimmune diseases, hypercholesterolemia, liver failure and sepsis.   
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